AU2019474692B2 - Personal care compositions for treating odor causing bacteria and methods for the same - Google Patents
Personal care compositions for treating odor causing bacteria and methods for the same Download PDFInfo
- Publication number
- AU2019474692B2 AU2019474692B2 AU2019474692A AU2019474692A AU2019474692B2 AU 2019474692 B2 AU2019474692 B2 AU 2019474692B2 AU 2019474692 A AU2019474692 A AU 2019474692A AU 2019474692 A AU2019474692 A AU 2019474692A AU 2019474692 B2 AU2019474692 B2 AU 2019474692B2
- Authority
- AU
- Australia
- Prior art keywords
- composition
- skin
- weight
- bacteria
- growth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 204
- 238000000034 method Methods 0.000 title claims abstract description 73
- 241000894006 Bacteria Species 0.000 title claims abstract description 70
- 150000002191 fatty alcohols Chemical class 0.000 claims abstract description 50
- 230000009286 beneficial effect Effects 0.000 claims abstract description 30
- 230000001627 detrimental effect Effects 0.000 claims abstract description 29
- 230000001737 promoting effect Effects 0.000 claims abstract description 20
- 241000192125 Firmicutes Species 0.000 claims abstract description 18
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 16
- XMVBHZBLHNOQON-UHFFFAOYSA-N 2-butyl-1-octanol Chemical compound CCCCCCC(CO)CCCC XMVBHZBLHNOQON-UHFFFAOYSA-N 0.000 claims description 60
- 230000001166 anti-perspirative effect Effects 0.000 claims description 35
- 239000003213 antiperspirant Substances 0.000 claims description 35
- 239000002781 deodorant agent Substances 0.000 claims description 30
- 241000191940 Staphylococcus Species 0.000 claims description 28
- 241000186216 Corynebacterium Species 0.000 claims description 18
- 230000001603 reducing effect Effects 0.000 claims description 14
- 241000191963 Staphylococcus epidermidis Species 0.000 claims description 11
- 102000044503 Antimicrobial Peptides Human genes 0.000 claims description 9
- 108700042778 Antimicrobial Peptides Proteins 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 239000006210 lotion Substances 0.000 claims description 8
- 239000006071 cream Substances 0.000 claims description 6
- 230000002708 enhancing effect Effects 0.000 claims description 6
- 241000191984 Staphylococcus haemolyticus Species 0.000 claims description 5
- 239000000839 emulsion Substances 0.000 claims description 5
- CAYHVMBQBLYQMT-UHFFFAOYSA-N 2-decyltetradecan-1-ol Chemical compound CCCCCCCCCCCCC(CO)CCCCCCCCCC CAYHVMBQBLYQMT-UHFFFAOYSA-N 0.000 claims description 3
- DEMBLPGWNXUBIQ-UHFFFAOYSA-N 2-dodecylhexadecan-1-ol Chemical compound CCCCCCCCCCCCCCC(CO)CCCCCCCCCCCC DEMBLPGWNXUBIQ-UHFFFAOYSA-N 0.000 claims description 3
- KPDUZRFOMCTGPM-UHFFFAOYSA-N 2-heptadecylhenicosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCC(CO)CCCCCCCCCCCCCCCCC KPDUZRFOMCTGPM-UHFFFAOYSA-N 0.000 claims description 3
- YEGNTQBFSQBGJT-UHFFFAOYSA-N 2-heptylundecan-1-ol Chemical compound CCCCCCCCCC(CO)CCCCCCC YEGNTQBFSQBGJT-UHFFFAOYSA-N 0.000 claims description 3
- JQJGGMZIMBGQQY-UHFFFAOYSA-N 2-hexadecylicosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCC(CO)CCCCCCCCCCCCCCCC JQJGGMZIMBGQQY-UHFFFAOYSA-N 0.000 claims description 3
- XULHFMYCBKQGEE-UHFFFAOYSA-N 2-hexyl-1-Decanol Chemical compound CCCCCCCCC(CO)CCCCCC XULHFMYCBKQGEE-UHFFFAOYSA-N 0.000 claims description 3
- JSIOIMBOKALMPC-UHFFFAOYSA-N 2-icosyltetracosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCC(CO)CCCCCCCCCCCCCCCCCCCC JSIOIMBOKALMPC-UHFFFAOYSA-N 0.000 claims description 3
- CDRGJQOGLJTFHQ-UHFFFAOYSA-N 2-nonadecyltricosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(CO)CCCCCCCCCCCCCCCCCCC CDRGJQOGLJTFHQ-UHFFFAOYSA-N 0.000 claims description 3
- PDBKSKNFOPOYTP-UHFFFAOYSA-N 2-nonyltridecan-1-ol Chemical compound CCCCCCCCCCCC(CO)CCCCCCCCC PDBKSKNFOPOYTP-UHFFFAOYSA-N 0.000 claims description 3
- CHPRNYDWAOQKSK-UHFFFAOYSA-N 2-octadecyldocosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCC(CO)CCCCCCCCCCCCCCCCCC CHPRNYDWAOQKSK-UHFFFAOYSA-N 0.000 claims description 3
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 claims description 3
- JPTRUQGKLMQGMD-UHFFFAOYSA-N 2-pentadecylnonadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCC(CO)CCCCCCCCCCCCCCC JPTRUQGKLMQGMD-UHFFFAOYSA-N 0.000 claims description 3
- DHMRGSATSWRQFT-UHFFFAOYSA-N 2-pentylnonan-1-ol Chemical compound CCCCCCCC(CO)CCCCC DHMRGSATSWRQFT-UHFFFAOYSA-N 0.000 claims description 3
- RTXVDAJGIYOHFY-UHFFFAOYSA-N 2-tetradecyloctadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCC(CO)CCCCCCCCCCCCCC RTXVDAJGIYOHFY-UHFFFAOYSA-N 0.000 claims description 3
- XYVXFHBIYUGIFM-UHFFFAOYSA-N 2-tridecylheptadecan-1-ol Chemical compound CCCCCCCCCCCCCCCC(CO)CCCCCCCCCCCCC XYVXFHBIYUGIFM-UHFFFAOYSA-N 0.000 claims description 3
- CYSSSYKSBHKJQE-UHFFFAOYSA-N 2-undecylpentadecan-1-ol Chemical compound CCCCCCCCCCCCCC(CO)CCCCCCCCCCC CYSSSYKSBHKJQE-UHFFFAOYSA-N 0.000 claims description 3
- 230000002951 depilatory effect Effects 0.000 claims description 3
- 210000001577 neostriatum Anatomy 0.000 claims description 3
- 239000002453 shampoo Substances 0.000 claims description 3
- 230000000475 sunscreen effect Effects 0.000 claims description 3
- 239000000516 sunscreening agent Substances 0.000 claims description 3
- XULHFMYCBKQGEE-MRXNPFEDSA-N 2-Hexyl-1-decanol Natural products CCCCCCCC[C@H](CO)CCCCCC XULHFMYCBKQGEE-MRXNPFEDSA-N 0.000 claims description 2
- -1 2-butyl octanol Chemical class 0.000 description 42
- 241000124008 Mammalia Species 0.000 description 27
- 229920001296 polysiloxane Polymers 0.000 description 25
- 239000000463 material Substances 0.000 description 21
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 18
- 229960003237 betaine Drugs 0.000 description 18
- 239000007787 solid Substances 0.000 description 16
- 150000003839 salts Chemical class 0.000 description 15
- 239000002585 base Substances 0.000 description 14
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 13
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- 239000003974 emollient agent Substances 0.000 description 12
- 239000004615 ingredient Substances 0.000 description 12
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 11
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 10
- 239000004205 dimethyl polysiloxane Substances 0.000 description 10
- 150000002148 esters Chemical class 0.000 description 10
- 229940086555 cyclomethicone Drugs 0.000 description 9
- 239000008173 hydrogenated soybean oil Substances 0.000 description 9
- 239000004094 surface-active agent Substances 0.000 description 9
- 229940008099 dimethicone Drugs 0.000 description 8
- 229930195733 hydrocarbon Natural products 0.000 description 8
- 150000002430 hydrocarbons Chemical class 0.000 description 8
- 235000019645 odor Nutrition 0.000 description 8
- 239000004215 Carbon black (E152) Substances 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 7
- 230000004888 barrier function Effects 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 239000002736 nonionic surfactant Substances 0.000 description 7
- 230000001717 pathogenic effect Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- ICIDSZQHPUZUHC-UHFFFAOYSA-N 2-octadecoxyethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCO ICIDSZQHPUZUHC-UHFFFAOYSA-N 0.000 description 6
- 239000004359 castor oil Substances 0.000 description 6
- 235000019438 castor oil Nutrition 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 5
- 229910019142 PO4 Inorganic materials 0.000 description 5
- 125000003118 aryl group Chemical group 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 239000003349 gelling agent Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 239000010452 phosphate Substances 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- WYANSMZYIOPJFV-UHFFFAOYSA-L aluminum;2-aminoacetic acid;zirconium(4+);chloride;hydroxide;hydrate Chemical compound O.[OH-].[Al+3].[Cl-].[Zr+4].NCC(O)=O WYANSMZYIOPJFV-UHFFFAOYSA-L 0.000 description 4
- HAMGNFFXQJOFRZ-UHFFFAOYSA-L aluminum;zirconium(4+);chloride;hydroxide;hydrate Chemical compound O.[OH-].[Al+3].[Cl-].[Zr+4] HAMGNFFXQJOFRZ-UHFFFAOYSA-L 0.000 description 4
- 239000002280 amphoteric surfactant Substances 0.000 description 4
- 159000000007 calcium salts Chemical class 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 239000011630 iodine Substances 0.000 description 4
- 229910052740 iodine Inorganic materials 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
- 229940068968 polysorbate 80 Drugs 0.000 description 4
- 229920000053 polysorbate 80 Polymers 0.000 description 4
- 229960004063 propylene glycol Drugs 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 239000004166 Lanolin Substances 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 3
- YCLAMANSVUJYPT-UHFFFAOYSA-L aluminum chloride hydroxide hydrate Chemical compound O.[OH-].[Al+3].[Cl-] YCLAMANSVUJYPT-UHFFFAOYSA-L 0.000 description 3
- 229940053431 aluminum sesquichlorohydrate Drugs 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 229940039717 lanolin Drugs 0.000 description 3
- 235000019388 lanolin Nutrition 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
- 125000005702 oxyalkylene group Chemical group 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 229940100459 steareth-20 Drugs 0.000 description 3
- 229940100458 steareth-21 Drugs 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 229910052726 zirconium Inorganic materials 0.000 description 3
- 239000002888 zwitterionic surfactant Substances 0.000 description 3
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 2
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 2
- ILCOCZBHMDEIAI-UHFFFAOYSA-N 2-(2-octadecoxyethoxy)ethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCOCCO ILCOCZBHMDEIAI-UHFFFAOYSA-N 0.000 description 2
- ZVUNTIMPQCQCAQ-UHFFFAOYSA-N 2-dodecanoyloxyethyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCC ZVUNTIMPQCQCAQ-UHFFFAOYSA-N 0.000 description 2
- SFAAOBGYWOUHLU-UHFFFAOYSA-N 2-ethylhexyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(CC)CCCC SFAAOBGYWOUHLU-UHFFFAOYSA-N 0.000 description 2
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 2
- JYCQQPHGFMYQCF-UHFFFAOYSA-N 4-tert-Octylphenol monoethoxylate Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCO)C=C1 JYCQQPHGFMYQCF-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- 241000158523 Corynebacterium striatum Species 0.000 description 2
- 241000194031 Enterococcus faecium Species 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 208000012868 Overgrowth Diseases 0.000 description 2
- 241000286209 Phasianidae Species 0.000 description 2
- 241000218657 Picea Species 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical group [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 2
- ZGUQGPFMMTZGBQ-UHFFFAOYSA-N [Al].[Al].[Zr] Chemical group [Al].[Al].[Zr] ZGUQGPFMMTZGBQ-UHFFFAOYSA-N 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- DNXNYEBMOSARMM-UHFFFAOYSA-N alumane;zirconium Chemical compound [AlH3].[Zr] DNXNYEBMOSARMM-UHFFFAOYSA-N 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 239000003945 anionic surfactant Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- LVYZJEPLMYTTGH-UHFFFAOYSA-H dialuminum chloride pentahydroxide dihydrate Chemical compound [Cl-].[Al+3].[OH-].[OH-].[Al+3].[OH-].[OH-].[OH-].O.O LVYZJEPLMYTTGH-UHFFFAOYSA-H 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- QMCVOSQFZZCSLN-VAWYXSNFSA-N dihexyl (e)-but-2-enedioate Chemical compound CCCCCCOC(=O)\C=C\C(=O)OCCCCCC QMCVOSQFZZCSLN-VAWYXSNFSA-N 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 229940075507 glyceryl monostearate Drugs 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- 239000007764 o/w emulsion Substances 0.000 description 2
- CNNRPFQICPFDPO-UHFFFAOYSA-N octacosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCO CNNRPFQICPFDPO-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 229920002113 octoxynol Polymers 0.000 description 2
- 229940049964 oleate Drugs 0.000 description 2
- 244000039328 opportunistic pathogen Species 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 2
- 229920000570 polyether Polymers 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 230000003381 solubilizing effect Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 229940098760 steareth-2 Drugs 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 125000003107 substituted aryl group Chemical group 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- DIORMHZUUKOISG-UHFFFAOYSA-N sulfoformic acid Chemical compound OC(=O)S(O)(=O)=O DIORMHZUUKOISG-UHFFFAOYSA-N 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- MHXBHWLGRWOABW-UHFFFAOYSA-N tetradecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC MHXBHWLGRWOABW-UHFFFAOYSA-N 0.000 description 2
- CRDAMVZIKSXKFV-UHFFFAOYSA-N trans-Farnesol Natural products CC(C)=CCCC(C)=CCCC(C)=CCO CRDAMVZIKSXKFV-UHFFFAOYSA-N 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- ICUTUKXCWQYESQ-UHFFFAOYSA-N triclocarban Chemical compound C1=CC(Cl)=CC=C1NC(=O)NC1=CC=C(Cl)C(Cl)=C1 ICUTUKXCWQYESQ-UHFFFAOYSA-N 0.000 description 2
- 239000001974 tryptic soy broth Substances 0.000 description 2
- 108010050327 trypticase-soy broth Proteins 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- CRDAMVZIKSXKFV-FBXUGWQNSA-N (2-cis,6-cis)-farnesol Chemical compound CC(C)=CCC\C(C)=C/CC\C(C)=C/CO CRDAMVZIKSXKFV-FBXUGWQNSA-N 0.000 description 1
- 239000000260 (2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-ol Substances 0.000 description 1
- SQXCNVUDTUUSNZ-KAQMDTKVSA-N (2r,3s,4r,5r)-2-amino-2,3,4,5,6-pentahydroxyhexanoic acid Chemical compound OC(=O)[C@@](O)(N)[C@@H](O)[C@H](O)[C@H](O)CO SQXCNVUDTUUSNZ-KAQMDTKVSA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- QMMJWQMCMRUYTG-UHFFFAOYSA-N 1,2,4,5-tetrachloro-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl QMMJWQMCMRUYTG-UHFFFAOYSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
- 229960002666 1-octacosanol Drugs 0.000 description 1
- WAYINTBTZWQNSN-UHFFFAOYSA-N 11-methyldodecyl 3,5,5-trimethylhexanoate Chemical compound CC(C)CCCCCCCCCCOC(=O)CC(C)CC(C)(C)C WAYINTBTZWQNSN-UHFFFAOYSA-N 0.000 description 1
- LGEZTMRIZWCDLW-UHFFFAOYSA-N 14-methylpentadecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC(C)C LGEZTMRIZWCDLW-UHFFFAOYSA-N 0.000 description 1
- JSOVGYMVTPPEND-UHFFFAOYSA-N 16-methylheptadecyl 2,2-dimethylpropanoate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)C(C)(C)C JSOVGYMVTPPEND-UHFFFAOYSA-N 0.000 description 1
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- JKTAIYGNOFSMCE-UHFFFAOYSA-N 2,3-di(nonyl)phenol Chemical compound CCCCCCCCCC1=CC=CC(O)=C1CCCCCCCCC JKTAIYGNOFSMCE-UHFFFAOYSA-N 0.000 description 1
- XFOQWQKDSMIPHT-UHFFFAOYSA-N 2,3-dichloro-6-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CC=C(Cl)C(Cl)=N1 XFOQWQKDSMIPHT-UHFFFAOYSA-N 0.000 description 1
- HDIFHQMREAYYJW-FMIVXFBMSA-N 2,3-dihydroxypropyl (e)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C\CCCCCCCC(=O)OCC(O)CO HDIFHQMREAYYJW-FMIVXFBMSA-N 0.000 description 1
- PWVUXRBUUYZMKM-UHFFFAOYSA-N 2-(2-hydroxyethoxy)ethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOCCO PWVUXRBUUYZMKM-UHFFFAOYSA-N 0.000 description 1
- MJQVZIANGRDJBT-VAWYXSNFSA-N 2-Phenylethyl 3-phenyl-2-propenoate Chemical compound C=1C=CC=CC=1/C=C/C(=O)OCCC1=CC=CC=C1 MJQVZIANGRDJBT-VAWYXSNFSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- KWVPFECTOKLOBL-KTKRTIGZSA-N 2-[(z)-octadec-9-enoxy]ethanol Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCO KWVPFECTOKLOBL-KTKRTIGZSA-N 0.000 description 1
- PLFJWWUZKJKIPZ-UHFFFAOYSA-N 2-[2-[2-(2,6,8-trimethylnonan-4-yloxy)ethoxy]ethoxy]ethanol Chemical compound CC(C)CC(C)CC(CC(C)C)OCCOCCOCCO PLFJWWUZKJKIPZ-UHFFFAOYSA-N 0.000 description 1
- DWHIUNMOTRUVPG-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCO DWHIUNMOTRUVPG-UHFFFAOYSA-N 0.000 description 1
- MWEOKSUOWKDVIK-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCOCCOCCOCCOCCOCCOCCOCCO MWEOKSUOWKDVIK-UHFFFAOYSA-N 0.000 description 1
- NLMKTBGFQGKQEV-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-hexadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO NLMKTBGFQGKQEV-UHFFFAOYSA-N 0.000 description 1
- JKXYOQDLERSFPT-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-octadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO JKXYOQDLERSFPT-UHFFFAOYSA-N 0.000 description 1
- OPJWPPVYCOPDCM-UHFFFAOYSA-N 2-ethylhexyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(CC)CCCC OPJWPPVYCOPDCM-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- OJIBJRXMHVZPLV-UHFFFAOYSA-N 2-methylpropyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(C)C OJIBJRXMHVZPLV-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- IFKANGOXGBPILW-UHFFFAOYSA-N 3,4-dihydro-2h-chromene-6-carboxylic acid Chemical compound O1CCCC2=CC(C(=O)O)=CC=C21 IFKANGOXGBPILW-UHFFFAOYSA-N 0.000 description 1
- UIVPNOBLHXUKDX-UHFFFAOYSA-N 3,5,5-trimethylhexyl 3,5,5-trimethylhexanoate Chemical compound CC(C)(C)CC(C)CCOC(=O)CC(C)CC(C)(C)C UIVPNOBLHXUKDX-UHFFFAOYSA-N 0.000 description 1
- NCZPCONIKBICGS-UHFFFAOYSA-N 3-(2-ethylhexoxy)propane-1,2-diol Chemical compound CCCCC(CC)COCC(O)CO NCZPCONIKBICGS-UHFFFAOYSA-N 0.000 description 1
- OSPOJLWAJPWJTO-UHFFFAOYSA-N 3-[hexadecyl(dimethyl)azaniumyl]-2-hydroxypropane-1-sulfonate Chemical compound CCCCCCCCCCCCCCCC[N+](C)(C)CC(O)CS([O-])(=O)=O OSPOJLWAJPWJTO-UHFFFAOYSA-N 0.000 description 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
- XXBAQTDVRLRXEV-UHFFFAOYSA-N 3-tetradecoxypropan-1-ol Chemical compound CCCCCCCCCCCCCCOCCCO XXBAQTDVRLRXEV-UHFFFAOYSA-N 0.000 description 1
- QISOBCMNUJQOJU-UHFFFAOYSA-N 4-bromo-1h-pyrazole-5-carboxylic acid Chemical compound OC(=O)C=1NN=CC=1Br QISOBCMNUJQOJU-UHFFFAOYSA-N 0.000 description 1
- HBTAOSGHCXUEKI-UHFFFAOYSA-N 4-chloro-n,n-dimethyl-3-nitrobenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 HBTAOSGHCXUEKI-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- UWQGQQYXWFQSQC-UHFFFAOYSA-N 5-[bis(2-hydroxyethyl)-octadecylazaniumyl]pentanoate Chemical compound CCCCCCCCCCCCCCCCCC[N+](CCO)(CCO)CCCCC([O-])=O UWQGQQYXWFQSQC-UHFFFAOYSA-N 0.000 description 1
- AMEMLELAMQEAIA-UHFFFAOYSA-N 6-(tert-butyl)thieno[3,2-d]pyrimidin-4(3H)-one Chemical compound N1C=NC(=O)C2=C1C=C(C(C)(C)C)S2 AMEMLELAMQEAIA-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- BRORPGSJXSLXKN-UHFFFAOYSA-N 6-methylheptyl 3,5,5-trimethylhexanoate Chemical compound CC(C)CCCCCOC(=O)CC(C)CC(C)(C)C BRORPGSJXSLXKN-UHFFFAOYSA-N 0.000 description 1
- ODMZDMMTKHXXKA-QXMHVHEDSA-N 8-methylnonyl (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCCCCCCCC(C)C ODMZDMMTKHXXKA-QXMHVHEDSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-M Aminoacetate Chemical compound NCC([O-])=O DHMQDGOQFOQNFH-UHFFFAOYSA-M 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 241000272517 Anseriformes Species 0.000 description 1
- 101100377893 Arabidopsis thaliana ABIL3 gene Proteins 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000193755 Bacillus cereus Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 208000035985 Body Odor Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 125000006539 C12 alkyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- DHRWDMXZWIUYLA-UHFFFAOYSA-N CCCCCCC(CO)CCCC.CCCCCCC(CO)CCCC Chemical compound CCCCCCC(CO)CCCC.CCCCCCC(CO)CCCC DHRWDMXZWIUYLA-UHFFFAOYSA-N 0.000 description 1
- OKORAVWNQQYVNK-UHFFFAOYSA-N CCCCCCCCCCCC[P+](C)(C)CCCP([O-])(O)=O Chemical compound CCCCCCCCCCCC[P+](C)(C)CCCP([O-])(O)=O OKORAVWNQQYVNK-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241000193155 Clostridium botulinum Species 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 241000193449 Clostridium tetani Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000186227 Corynebacterium diphtheriae Species 0.000 description 1
- 241000918600 Corynebacterium ulcerans Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical class S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 241000271571 Dromaius novaehollandiae Species 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Natural products OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- CMBYOWLFQAFZCP-UHFFFAOYSA-N Hexyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCCCCC CMBYOWLFQAFZCP-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241000270322 Lepidosauria Species 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- YLCXGBZIZBEVPZ-UHFFFAOYSA-N Medazepam Chemical compound C12=CC(Cl)=CC=C2N(C)CCN=C1C1=CC=CC=C1 YLCXGBZIZBEVPZ-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GWFGDXZQZYMSMJ-UHFFFAOYSA-N Octadecansaeure-heptadecylester Natural products CCCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCCCC GWFGDXZQZYMSMJ-UHFFFAOYSA-N 0.000 description 1
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101100189030 Oryza sativa subsp. japonica PP2C50 gene Proteins 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000191992 Peptostreptococcus Species 0.000 description 1
- 241000192035 Peptostreptococcus anaerobius Species 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 229920002413 Polyhexanide Polymers 0.000 description 1
- 229920002701 Polyoxyl 40 Stearate Polymers 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920001219 Polysorbate 40 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 241000287530 Psittaciformes Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 206010040904 Skin odour abnormal Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000192087 Staphylococcus hominis Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 241000272534 Struthio camelus Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- BGYHLZZASRKEJE-UHFFFAOYSA-N [3-[3-(3,5-ditert-butyl-4-hydroxyphenyl)propanoyloxy]-2,2-bis[3-(3,5-ditert-butyl-4-hydroxyphenyl)propanoyloxymethyl]propyl] 3-(3,5-ditert-butyl-4-hydroxyphenyl)propanoate Chemical compound CC(C)(C)C1=C(O)C(C(C)(C)C)=CC(CCC(=O)OCC(COC(=O)CCC=2C=C(C(O)=C(C=2)C(C)(C)C)C(C)(C)C)(COC(=O)CCC=2C=C(C(O)=C(C=2)C(C)(C)C)C(C)(C)C)COC(=O)CCC=2C=C(C(O)=C(C=2)C(C)(C)C)C(C)(C)C)=C1 BGYHLZZASRKEJE-UHFFFAOYSA-N 0.000 description 1
- 229940048299 acetylated lanolin alcohols Drugs 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229940099583 aluminum starch octenylsuccinate Drugs 0.000 description 1
- 229940071540 aluminum zirconium octachlorohydrex gly Drugs 0.000 description 1
- 229940048496 aluminum zirconium pentachlorohydrex gly Drugs 0.000 description 1
- 229940048506 aluminum zirconium tetrachlorohydrex gly Drugs 0.000 description 1
- 229940072028 aluminum zirconium trichlorohydrex gly Drugs 0.000 description 1
- YXZZLAMCXFHTTE-UHFFFAOYSA-N aluminum;propane-1,2-diol;trihypochlorite;hydrate Chemical compound O.[Al+3].Cl[O-].Cl[O-].Cl[O-].CC(O)CO YXZZLAMCXFHTTE-UHFFFAOYSA-N 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 125000000656 azaniumyl group Chemical group [H][N+]([H])([H])[*] 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 239000001518 benzyl (E)-3-phenylprop-2-enoate Substances 0.000 description 1
- NGHOLYJTSCBCGC-QXMHVHEDSA-N benzyl cinnamate Chemical compound C=1C=CC=CC=1\C=C/C(=O)OCC1=CC=CC=C1 NGHOLYJTSCBCGC-QXMHVHEDSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- SAOKZLXYCUGLFA-UHFFFAOYSA-N bis(2-ethylhexyl) adipate Chemical compound CCCCC(CC)COC(=O)CCCCC(=O)OCC(CC)CCCC SAOKZLXYCUGLFA-UHFFFAOYSA-N 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 1
- DHAZIUXMHRHVMP-UHFFFAOYSA-N butyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCCCC DHAZIUXMHRHVMP-UHFFFAOYSA-N 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 229960001777 castor oil Drugs 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 229940056318 ceteth-20 Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- NGHOLYJTSCBCGC-UHFFFAOYSA-N cis-cinnamic acid benzyl ester Natural products C=1C=CC=CC=1C=CC(=O)OCC1=CC=CC=C1 NGHOLYJTSCBCGC-UHFFFAOYSA-N 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 229910052570 clay Inorganic materials 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- SASYSVUEVMOWPL-NXVVXOECSA-N decyl oleate Chemical compound CCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC SASYSVUEVMOWPL-NXVVXOECSA-N 0.000 description 1
- XILPPDQAWPSZIL-UHFFFAOYSA-H dialuminum;dichloride;tetrahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[Al+3].[Al+3].[Cl-].[Cl-] XILPPDQAWPSZIL-UHFFFAOYSA-H 0.000 description 1
- KNXDJTLIRRQLBE-UHFFFAOYSA-H dialuminum;propane-1,2-diol;chloride;pentahydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[OH-].[OH-].[Al+3].[Al+3].[Cl-].CC(O)CO KNXDJTLIRRQLBE-UHFFFAOYSA-H 0.000 description 1
- 229940031768 diglycol stearate Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 229940031578 diisopropyl adipate Drugs 0.000 description 1
- 229940031569 diisopropyl sebacate Drugs 0.000 description 1
- XFKBBSZEQRFVSL-UHFFFAOYSA-N dipropan-2-yl decanedioate Chemical compound CC(C)OC(=O)CCCCCCCCC(=O)OC(C)C XFKBBSZEQRFVSL-UHFFFAOYSA-N 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- QQQMUBLXDAFBRH-UHFFFAOYSA-N dodecyl 2-hydroxypropanoate Chemical compound CCCCCCCCCCCCOC(=O)C(C)O QQQMUBLXDAFBRH-UHFFFAOYSA-N 0.000 description 1
- GVGUFUZHNYFZLC-UHFFFAOYSA-N dodecyl benzenesulfonate;sodium Chemical compound [Na].CCCCCCCCCCCCOS(=O)(=O)C1=CC=CC=C1 GVGUFUZHNYFZLC-UHFFFAOYSA-N 0.000 description 1
- DLAHAXOYRFRPFQ-UHFFFAOYSA-N dodecyl benzoate Chemical compound CCCCCCCCCCCCOC(=O)C1=CC=CC=C1 DLAHAXOYRFRPFQ-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229940043259 farnesol Drugs 0.000 description 1
- 229930002886 farnesol Natural products 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
- 238000011331 genomic analysis Methods 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- GTABBGRXERZUAH-UHFFFAOYSA-N hexadecan-1-ol;2-methyloxirane;oxirane Chemical compound C1CO1.CC1CO1.CCCCCCCCCCCCCCCCO GTABBGRXERZUAH-UHFFFAOYSA-N 0.000 description 1
- 229940100463 hexyl laurate Drugs 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940078545 isocetyl stearate Drugs 0.000 description 1
- 229940100554 isononyl isononanoate Drugs 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229940093629 isopropyl isostearate Drugs 0.000 description 1
- 229940033357 isopropyl laurate Drugs 0.000 description 1
- 229940074928 isopropyl myristate Drugs 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 229940075495 isopropyl palmitate Drugs 0.000 description 1
- 229940089456 isopropyl stearate Drugs 0.000 description 1
- 229940031674 laureth-7 Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 239000008308 lipophilic cream Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 229940078812 myristyl myristate Drugs 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- NKBWPOSQERPBFI-UHFFFAOYSA-N octadecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCCCC NKBWPOSQERPBFI-UHFFFAOYSA-N 0.000 description 1
- 229960001679 octinoxate Drugs 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940060184 oil ingredients Drugs 0.000 description 1
- 229940093446 oleth-5 Drugs 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 125000000963 oxybis(methylene) group Chemical group [H]C([H])(*)OC([H])([H])* 0.000 description 1
- 125000006353 oxyethylene group Chemical group 0.000 description 1
- 229940017686 palm kernel glycerides Drugs 0.000 description 1
- 235000019809 paraffin wax Nutrition 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229940100460 peg-100 stearate Drugs 0.000 description 1
- 229940102545 peg-20 sorbitan isostearate Drugs 0.000 description 1
- 229940032041 peg-8 laurate Drugs 0.000 description 1
- 229940074571 peptostreptococcus anaerobius Drugs 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940057874 phenyl trimethicone Drugs 0.000 description 1
- XYFCBTPGUUZFHI-UHFFFAOYSA-O phosphonium Chemical compound [PH4+] XYFCBTPGUUZFHI-UHFFFAOYSA-O 0.000 description 1
- 239000010773 plant oil Substances 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 229920001521 polyalkylene glycol ether Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 1
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940101027 polysorbate 40 Drugs 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229940116987 ppg-3 myristyl ether Drugs 0.000 description 1
- XEIOPEQGDSYOIH-MURFETPASA-N propan-2-yl (9z,12z)-octadeca-9,12-dienoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC(C)C XEIOPEQGDSYOIH-MURFETPASA-N 0.000 description 1
- NEOZOXKVMDBOSG-UHFFFAOYSA-N propan-2-yl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OC(C)C NEOZOXKVMDBOSG-UHFFFAOYSA-N 0.000 description 1
- ZPWFUIUNWDIYCJ-UHFFFAOYSA-N propan-2-yl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(C)C ZPWFUIUNWDIYCJ-UHFFFAOYSA-N 0.000 description 1
- KCXFHTAICRTXLI-UHFFFAOYSA-M propane-1-sulfonate Chemical compound CCCS([O-])(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-M 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- YLQLIQIAXYRMDL-UHFFFAOYSA-N propylheptyl alcohol Chemical compound CCCCCC(CO)CCC YLQLIQIAXYRMDL-UHFFFAOYSA-N 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940080264 sodium dodecylbenzenesulfonate Drugs 0.000 description 1
- 229940079862 sodium lauryl sarcosinate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- ADWNFGORSPBALY-UHFFFAOYSA-M sodium;2-[dodecyl(methyl)amino]acetate Chemical compound [Na+].CCCCCCCCCCCCN(C)CC([O-])=O ADWNFGORSPBALY-UHFFFAOYSA-M 0.000 description 1
- IWMMSZLFZZPTJY-UHFFFAOYSA-M sodium;3-(dodecylamino)propane-1-sulfonate Chemical compound [Na+].CCCCCCCCCCCCNCCCS([O-])(=O)=O IWMMSZLFZZPTJY-UHFFFAOYSA-M 0.000 description 1
- HWCHICTXVOMIIF-UHFFFAOYSA-M sodium;3-(dodecylamino)propanoate Chemical compound [Na+].CCCCCCCCCCCCNCCC([O-])=O HWCHICTXVOMIIF-UHFFFAOYSA-M 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 229950011392 sorbitan stearate Drugs 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 229940037649 staphylococcus haemolyticus Drugs 0.000 description 1
- 229940114926 stearate Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- BORJONZPSTVSFP-UHFFFAOYSA-N tetradecyl 2-hydroxypropanoate Chemical compound CCCCCCCCCCCCCCOC(=O)C(C)O BORJONZPSTVSFP-UHFFFAOYSA-N 0.000 description 1
- DZKXJUASMGQEMA-UHFFFAOYSA-N tetradecyl tetradecanoate Chemical compound CCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCC DZKXJUASMGQEMA-UHFFFAOYSA-N 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- WWSBQOYADFGDQE-UHFFFAOYSA-N tridecanedioic acid dimethyl ester Natural products COC(=O)CCCCCCCCCCCC(=O)OC WWSBQOYADFGDQE-UHFFFAOYSA-N 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 1
- LINXHFKHZLOLEI-UHFFFAOYSA-N trimethyl-[phenyl-bis(trimethylsilyloxy)silyl]oxysilane Chemical compound C[Si](C)(C)O[Si](O[Si](C)(C)C)(O[Si](C)(C)C)C1=CC=CC=C1 LINXHFKHZLOLEI-UHFFFAOYSA-N 0.000 description 1
- ZQTYRTSKQFQYPQ-UHFFFAOYSA-N trisiloxane Chemical compound [SiH3]O[SiH2]O[SiH3] ZQTYRTSKQFQYPQ-UHFFFAOYSA-N 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- GAWWVVGZMLGEIW-GNNYBVKZSA-L zinc ricinoleate Chemical compound [Zn+2].CCCCCC[C@@H](O)C\C=C/CCCCCCCC([O-])=O.CCCCCC[C@@H](O)C\C=C/CCCCCCCC([O-])=O GAWWVVGZMLGEIW-GNNYBVKZSA-L 0.000 description 1
- 229940100530 zinc ricinoleate Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q15/00—Anti-perspirants or body deodorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/342—Alcohols having more than seven atoms in an unbroken chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
Abstract
Compositions, such as personal care compositions, and methods for selectively inhibiting the growth of a detrimental bacteria and promoting the growth of a beneficial bacteria are disclosed. The composition may include a base and one or more fatty alcohols. The one or more fatty alcohols may be present in an amount effective to selectively inhibit the growth of at least one detrimental Gram-positive bacteria and promote the growth of at least one beneficial Gram-positive bacteria on skin. The detrimental Gram-positive bacteria may include
Description
PERSONAL CARE COMPOSITIONS FOR TREATING ODOR CAUSING BACTERIA
AND METHODS FOR THE SAME
BACKGROUND
[1] Personal care compositions, such as antiperspirant/deodorant compositions, are often used to reduce the perspiration in an axillary (underarm) region and to treat or prevent the growth of bacteria in this region to thereby reduce or eliminate body odor. There is a wide array of bacteria that reside on our skin, especially in the axillary region. The most common bacterial genus on our skin is Staphylococcus bacteria, which includes Staphylococcus epidermidis, one of the most studied and known microbes. Staphylococcus epidermidis is a beneficial bacteria. Specifically, it produces antimicrobial peptides (AMP) and provides a barrier against the colonization of potentially pathogenic microbes and the overgrowth of opportunistic pathogens. While some bacteria, such as Staphylococcus epidermidis , have demonstrated some benefits to skin, other bacteria, such as Corynebacteria have proven to be undesirable. For example, there is ample evidence to indicate that Corynebacteria (Coryneforms) are the primary source of undesired, pungent underarm odors.
[2] What is needed, then, are improved personal care compositions, such as antiperspirant/deodorant compositions, that selectively inhibit, treat, or reduce the growth of detrimental bacteria, such as Corynebacteria , and/or promote the growth of beneficial bacteria, such as Staphylococcus epidermidis.
BRIEF SUMMARY
[3] This summary is intended merely to introduce a simplified summary of some aspects of one or more implementations of the present disclosure. Further areas of applicability of the present disclosure will become apparent from the detailed description provided hereinafter. This summary is not an extensive overview, nor is it intended to identify key or critical elements of the present teachings, nor to delineate the scope of the disclosure. Rather, its purpose is merely to present one or more concepts in simplified form as a prelude to the detailed description below.
[4] The foregoing and/or other aspects and utilities embodied in the present disclosure may be achieved by providing a composition including a base and one or more fatty alcohols. The one or more fatty alcohols may be present in an amount effective to selectively inhibit the growth of at
least one detrimental Gram-positive bacteria and promote the growth of at least one beneficial Gram-positive bacteria on skin.
[5] In at least one implementation, the one or more fatty alcohols may include one or more of 2-prop yl-heptanol, 2-butyl octanol, 2-pentyl- 1-nonanol, 2-hexyl- 1-decanol, 2-heptyl-l-undecanol, 2-octyl- 1-dodecanol, 2-nonyl-l-tridecanol, 2-decyl-tetradecanol, 2-undecyl-l-pentadecanol, 2- dodecyl-hexadecanol, 2-tridecyl-heptadecanol, 2-tetradecyl-l-octadecanol, 2-pentadecyl-l- nonadecanol, 2-hexadecyl-l-eicosanol, 2-heptadecyl-l-heneicosanol, 2-octadecyl-l-docosanol, 2- nonadecyl-l-tricosanol, 2-eicosyl-tetracosanol, or combinations thereof. In an exemplary implementation, the one or more fatty alcohols includes 2-butyl octanol.
[6] In at least one implementation, the one or more fatty alcohols may be present in an amount of from about 0.01 weight % to about 25 weight %, preferably about 0.01 weight % to about 5 weight %, more preferably in an amount of at least 0.16 weight% to about 5 weight %, or about 1.6 weight % to about 5 weight %, based on a total weight of the composition.
[7] In at least one implementation, the one or more fatty alcohols are present in an amount effective to selectively inhibit the growth of detrimental bacteria, such as Corynebacterium. For example, one or more fatty alcohols are present in an amount effective to selectively inhibit the growth of Cornebacterium striatum.
[8] In at least one implementation, the one or more fatty alcohols are present in an amount effective to selectively promote the growth of beneficial bacteria, such as Staphylococcus. For example the one or more fatty alcohols are present in an amount effective to selectively promote the growth of S. epidermidis, S. haemolyticus, or combinations thereof.
[9] In at least one implementation, the composition may be a personal care composition. The personal care composition may be or include a cleanser, a lotion, a cream, an emulsion, a shampoo, a conditioner, a shower gel, an antiperspirant, a deodorant, a depilatory, a lipstick, a foundation, a mascara, a sunless tanner, or a sunscreen lotion.
[10] In at least one implementation, the composition may include a deodorant active or an antiperspirant active.
[11] The foregoing and/or other aspects and utilities embodied in the present disclosure may be achieved by providing a method for selectively treating the growth of a detrimental bacteria and promoting the growth of a beneficial bacteria on skin. The method may include contacting any one of the compositions disclosed herein with the skin.
[12] In at least one implementation, the detrimental bacteria may include Corynebacterium.
[13] In at least one implementation, the beneficial bacteria may include Staphylococcus.
[14] In at least one implementation, the composition may be contacted with the skin daily for at least one week, at least two weeks, at least three weeks, or at least four weeks.
[15] The foregoing and/or other aspects and utilities embodied in the present disclosure may be achieved by providing a method for producing or enhancing the production of antimicrobial peptides on skin. The method may include contacting any one of the compositions disclosed herein with the skin.
[16] In at least one implementation, the method may further include promoting the growth of Staphylococcus on the skin to thereby produce or enhance the production of the antimicrobial peptides on the skin.
[17] In at least one implementation, the composition may be contacted with the skin daily for at least one week, at least two weeks, at least three weeks, or at least four weeks.
[18] The foregoing and/or other aspects and utilities embodied in the present disclosure may be achieved by providing a composition for use in treating or inhibiting the growth of a detrimental bacteria on skin. The composition may include a base and one or more fatty alcohols, wherein the one or more fatty alcohols are present in an amount effective to treat or inhibit the growth of the detrimental bacteria. The detrimental bacteria may include Corynebacterium.
[19] The foregoing and/or other aspects and utilities embodied in the present disclosure may be achieved by providing a composition for use in promoting the growth of a beneficial bacteria on skin. The composition may include a base and one or more fatty alcohols, wherein the one or more fatty alcohols are present in an amount effective to promote the growth of the beneficial bacteria. The beneficial bacteria may include Staphylococcus.
[20] The foregoing and/or other aspects and utilities embodied in the present disclosure may be achieved by providing a composition including a base and one or more fatty alcohols for use in selectively inhibiting the growth of at least one detrimental Gram-positive bacteria and promoting the growth of at least one beneficial Gram-positive bacteria on skin. The at least one detrimental Gram-positive bacteria may include Corynebacterium, optionally, Cornebacterium striatum. The at least one beneficial Gram-positive bacteria may include Staphylococcus, optionally, the Staphylococcus comprises S. epidermidis, S. haemolyticus, or combinations thereof.
[21] Further areas of applicability of the present disclosure will become apparent from the detailed description provided hereinafter. It should be understood that the detailed description and specific examples, while indicating some typical aspects of the disclosure, are intended for purposes of illustration only and are not intended to limit the scope of the disclosure.
DETAILED DESCRIPTION
[22] The following description of various typical aspect(s) is merely exemplary in nature and is in no way intended to limit the disclosure, its application, or uses.
[23] As used throughout this disclosure, ranges are used as shorthand for describing each and every value that is within the range. It should be appreciated and understood that the description in a range format is merely for convenience and brevity, and should not be construed as an inflexible limitation on the scope of any embodiments or implementations disclosed herein. Accordingly, the disclosed range should be construed to have specifically disclosed all the possible subranges as well as individual numerical values within that range. As such, any value within the range may be selected as the terminus of the range. For example, description of a range such as from 1 to 5 should be considered to have specifically disclosed subranges such as from 1.5 to 3, from 1 to 4.5, from 2 to 5, from 3.1 to 5, etc., as well as individual numbers within that range, for example, 1, 2, 3, 3.2, 4, 5, etc. This applies regardless of the breadth of the range.
[24] Unless otherwise specified, all percentages and amounts expressed herein and elsewhere in the specification should be understood to refer to percentages by weight. The amounts given are based on the active weight of the material.
[25] Additionally, all numerical values are “about” or “approximately” the indicated value, and take into account experimental error and variations that would be expected by a person having ordinary skill in the art. It should be appreciated that all numerical values and ranges disclosed herein are approximate values and ranges, whether “about” is used in conjunction therewith. It should also be appreciated that the term “about,” as used herein, in conjunction with a numeral refers to a value that may be ± 0.01% (inclusive), ± 0.1% (inclusive), ± 0.5% (inclusive), ± 1% (inclusive) of that numeral, ± 2% (inclusive) of that numeral, ± 3% (inclusive) of that numeral, ± 5% (inclusive) of that numeral, ± 10% (inclusive) of that numeral, or ± 15% (inclusive) of that numeral. It should further be appreciated that when a numerical range is disclosed herein, any numerical value falling within the range is also specifically disclosed.
[26] As used herein, “free” or “substantially free” of a material may refer to a composition, component, or phase where the material is present in an amount of less than 10.0 weight %, less than 5.0 weight %, less than 3.0 weight %, less than 1.0 weight %, less than 0.1 weight %, less than 0.05 weight %, less than 0.01 weight %, less than 0.005 weight %, or less than 0.0001 weight % based on a total weight of the composition, component, or phase.
[27] All references cited herein are hereby incorporated by reference in their entireties. In the event of a conflict in a definition in the present disclosure and that of a cited reference, the present disclosure controls.
[28] The present inventors have surprisingly and unexpectedly discovered that personal care compositions including one or more fatty alcohols, such as 2-butyl octanol, did not inhibit the growth of and/or promoted the growth of beneficial Gram-positive bacteria, such as Staphylococcus bacteria. The present inventors have also surprisingly and unexpectedly discovered that personal care compositions including one or more fatty alcohols, such as 2-butyl octanol, inhibit, treat, and/or reduce the growth of detrimental bacteria, such as Corynebacterium, especially when present in an amount of at least about 0.16 weight % or greater. The present inventors have further surprisingly and unexpectedly discovered that personal care compositions, such as deodorant or antiperspirant compositions, including one or more fatty alcohols, such as 2- butyl octanol, significantly and selectively reduced the relative abundance of detrimental bacteria (e.g., Corynebacteria ) and increased the relative abundance of beneficial bacteria (e.g., Staphylococcus ) .
COMPOSITIONS
[29] Compositions disclosed herein may be or include a personal care composition. As used herein, the term or expression “personal care composition” may refer to a composition for topical application to skin of mammals, especially humans. The personal care composition may generally be a leave-on personal care composition or rinse off personal care composition, and may include any product applied to a human body. The personal care composition is preferably a leave-on personal care composition. The personal care composition may be in any suitable form. Illustrative forms of the personal care composition may be or include, but is not limited to, a liquid, a lotion, a cream, a foam, a scrub, a gel, a soap bar, a toner, applied with an implement or via a face mask, or the like. Illustrative personal care compositions may be or include, but are not
limited to, cleansers, lotions, leave-on skin lotions and creams, emulsion, shampoos, conditioners, shower gels, antiperspirants, deodorants, depilatories, lipsticks, foundations, mascara, sunless tanners, sunscreen lotions, or the like.
[30] In an exemplary implementation, the compositions disclosed herein may be or include an antiperspirant composition, a deodorant composition, or combinations thereof. The compositions may include a base, an antiperspirant and/or a deodorant active, one or more fatty alcohols (e.g., 2-butyl- 1-octanol), or combinations thereof. The composition may be capable of or configured to treat, inhibit, and/or reduce detrimental bacteria on skin. The composition may be capable of treating, inhibiting, and/or reducing odor producing bacteria on skin, thereby reducing odor. The composition may also be capable of or configured to promote the growth of beneficial bacteria on skin. For example, as further described herein, the composition disclosed herein may be capable of or configured to treat, inhibit, and/or reduce the growth of Corynebacterium and/or promote the growth of Staphylococcus bacteria. The composition may further be capable of or configured to enhance or increase a barrier on the skin against colonization of potentially pathogenic microbes. For example, the composition may be capable of or configured to promote antimicrobial peptides (AMP) growth on the skin and provide a barrier against the colonization of potentially pathogenic microbes and the overgrowth of opportunistic pathogens on the skin.
[31] The composition may be in the form of an aqueous liquid, a gel, an aerosol, or a cream (e.g., “soft solid”). In the liquid form, the composition may be formulated to be a roll-on product. In the liquid form, the composition may be an oil in water emulsion or a water in oil emulsion. The forms of these products may be suspensions or emulsions. In one implementation, the composition is an oil in water liquid emulsion. The liquid may be contained in any roll on dispenser that has a ball for applying the composition to the surface of the skin. For example, the composition of the invention may be an oil-in-water liquid roll-on or a water-in-oil gel or a water- in-oil cream.
Fatty Alcohols
[32] The composition may include one or more fatty alcohols capable of or configured to treat, inhibit, and/or reduce detrimental bacteria. The one or more fatty alcohols may also be capable of or configured to promote the growth of beneficial bacteria on skin. For example, the one or more fatty alcohols may be capable of or configured to treat, inhibit, and/or reduce the growth of Corynebacterium and/or promote the growth of Staphylococcus bacteria. The fatty alcohols may
be linear alcohols or branched alcohols. The fatty alcohols may be saturated or unsaturated. Illustrative fatty alcohols may be or include, but are not limited to, C10-C45 branched fatty alcohols, 2-propyl-heptanol, 2-butyl- 1-octanol (2-butyl octanol), 2-pentyl- 1-nonanol, 2-hexyl-l- decanol, 2-heptyl-l-undecanol, 2-octyl- 1-dodecanol, 2-nonyl-l-tridecanol, 2-decyl-tetradecanol, 2-undecyl-l-pentadecanol, 2-dodecyl-hexadecanol, 2-tridecyl-heptadecanol, 2-tetradecyl-l- octadecanol, 2-pentadecyl-l-nonadecanol, 2-hexadecyl-l-eicosanol, 2-heptadecyl-l- heneicosanol, 2-octadecyl-l-docosanol, 2-nonadecyl-l-tricosanol, 2-eicosyl-tetracosanol, or the like, or any combination thereof. In an exemplary implementation, the one or more fatty alcohols include 2-butyl- 1-octanol or 2-butyl octanol.
[33] The one or more fatty alcohols may be present in an amount effective to treat, inhibit, and/or reduce detrimental bacteria on skin. The one or more fatty alcohols may also be present in an amount effective to treat, inhibit, and/or reduce odor producing bacteria on skin. The one or more fatty alcohols may further be present in an amount effective to promote the growth of beneficial bacteria on skin. The one or more fatty alcohols may also be present in an amount effective to enhance or increase a barrier on the skin against colonization of potentially pathogenic microbes. For example, the one or more fatty alcohols may be present in the composition in an amount effective to treat, inhibit, and/or reduce the growth of Corynebacterium and/or promote the growth of Staphylococcus bacteria. As used herein, an “effective amount,” or similar expressions, of a material or composition may refer to the amount needed to accomplish an intended purpose; for example, to treat, inhibit, and/or reduce detrimental bacteria on skin.
[34] In at least one implementation, the one or more fatty alcohols may be present in an amount of from greater than 0 weight % or about 0.01 weight % to about 25 weight %, based on a total weight of the composition. For example, the one or more fatty alcohols may be present in an amount of from greater than 0 weight %, about 0.01 weight %, about 0.02 weight %, about 0.04 weight %, about 0.08 weight %, about 0.16 weight %, about 0.20 weight %, about 0.25 weight %, about 0.5 weight %, about 0.75 weight %, about 1 weight %, about 1.6 weight %, about 2 weight %, about 5 weight %, about 8 weight %, or about 10 weight % to about 15 weight %, about 18 weight %, about 20 weight %, or about 25 weight %. In another exemplary implementation, the one or more fatty alcohols may be present in an amount of from about 0.01 weight % to about 25 weight % or about 0.01 weight % to about 5 weight %, based on a total weight of the composition. In another example, the one or more fatty alcohols may be present in an amount of at least 0.01
weight %, at least 0.02 weight %, at least 0.04 weight %, at least 0.08 weight %, at least 0.16 weight %, at least 0.20 weight %, at least 0.25 weight %, at least 0.5 weight %, at least 0.75 weight %, at least 1 weight %, at least 1.5 weight %, at least 1.6 weight %, at least 1.7 weight %, at least 1.8 weight %, at least 1.9 weight %, at least 2 weight %, at least 3 weight %, at least 4 weight %, at least 5 weight %, at least 8 weight %, at least 10 weight %, at least 15 weight %, at least 18 weight %, at least 20 weight %, or at least 25 weight %.
Antiperspirant Active
[35] The composition may include an antiperspirant active. Any of the known aluminum containing antiperspirant active materials may be utilized in the composition. Illustrative antiperspirant actives may be or include, but are not limited to, aluminum chlorohydrate, aluminum chloride, aluminum chlorohydrex polyethylene glycol, aluminum chlorohydrex propylene glycol, aluminum dichlorohydrate, aluminum dichlorohydrex polyethylene glycol, aluminum dichlorohydrex propylene glycol, aluminum sesquichlorohydrate, aluminum sesquichlorohydrate polyethylene glycol, aluminum sesquichlorohydrate propylene glycol, aluminum-zirconium octachlorohydrate, aluminum-zirconium octachlorohydrex gly, aluminum-zirconium pentachlorohydrate, aluminum-zirconium pentachlorohydrex gly, aluminum-zirconium tetrachlorohydrate, aluminum-zirconium tetrachlorohydrex gly, aluminum-zirconium trichlorohydrate, aluminum- zirconium trichlorohydrex gly, or the like, or any combination thereof. Generally, any of the Category I active antiperspirant ingredients, listed in the Food and Drug Administration's (FDA) Monograph on Antiperspirant Drug Products for over-the-counter human use (Oct. 10, 1973) may be used (21 CFR 350.10). In an exemplary implementation, the antiperspirant active is aluminum chlorohydrate. In another implementation, the antiperspirant active is aluminum zirconium tetrachlorhydrex propylene glycol.
[36] In at least one implementation, the antiperspirant active may be an aluminum salt and/or an aluminum- zirconium salt, such as those described above, that are further stabilized by betaine and a calcium salt. More information betaine and calcium salt stabilized antiperspirant salts may be found in U.S. Patent Application Publication No. 2006/0204463 to Tang et al. In other implementations, the antiperspirant active, such as those described above, is selected to have a low metal to chloride ratio. Examples of these antiperspirant actives may be found in U.S. Pat. No. 6,375,937 to Chopra et al. and in U.S. Patent Application Publication No. 2004/0109833 to Tang et al. The type of salt of interest, an aluminum zirconium tetrasalt or octasalt free of glycine may
be used wherein aluminum zirconium salt is stabilized by betaine and has a metal to chloride ratio of about 0.9:1 to about 1.3:1 (and in other embodiments of about 0.9:1 to about 1.2:1 or about 0.9:1 to about 1.1:1). For the tetrasalt, the Al/Zr atomic ratio may be about 3.2:1 to about 4.1:1.0 and the betaine: zirconium mole ratio may be about 0.2:1 to about 3.0:1 (or in other embodiments of about 0.4:l to about 1.5:1). Another salt that may be used is an aluminum chloride salt buffered by betaine, wherein the salt has a metal to chloride ratio of about 0.9: 1 to about 1.3:1 (and in other embodiments of about 0.9: 1 to about 1.2: 1 or about 0.9: 1 to about 1.1:1). For the octasalt the Al/Zr atomic ratio is about 6.2:1 to about 10.0:1 and the betaine:Zr mole ratio is about 0.2:1 to about 3.0:1 (or in other embodiments of about 0.4:1 to about 1.5:1). In one implementation, in the case of a salt that contains zirconium, the betaine is incorporated during the synthesis of the salt so as to maximize the stabilizing effect this ingredient has (especially on the zirconium species). Alternatively, it may be post added to a glycine-free salt along with additional active phase ingredients to form a betaine stabilized active. Additionally, the antiperspirant active may be a calcium salt stabilized antiperspirant active. Examples of calcium salt stabilized antiperspirant actives may be found in U.S. Patent Application Publication No. 2006/0204463.
[37] Examples of commercially available glycine-free low M:C1 ratio tetrasalts and octasalts may be or include, but are not limited to, REZAL™ AZP 955 CPG and REZAL™ AZP 885 respectively, which are both commercially available from SummitReheis Antiperspirant Actives of Huguenot, NY. A more detailed description of making such commercially available salts may be found for example, in U.S. Pat. Nos. 7,074,394 and 6,960,338. Further examples of making these types of salt complexes are described in U.S. Patent Application Publication No. 2004/0198998 and U.S. Pat. No. 7,105,691.
[38] Antiperspirant actives may be incorporated into the compositions in an effective amount to reduce the flow or generation of perspiration when applied to skin. For example, the composition may include any one or more of the antiperspirant actives in an amount of from about 1 weight % to about 30 weight %, on an actives basis, based on a total weight of the composition. Deodorant Active
[39] The composition may include one or more deodorant actives. Illustrative deodorant actives may be or include, but are not limited to, antimicrobial actives, alcohols, 2,4,4 '-trichloro-2'- hydroxy diphenyl ether (Triclosan), benzethonium chloride, polyhexamethylene biguanides, triethylcitrate, 2-amino-2-methyl-l -propanol (AMP), cetyl-trimethylammomium bromide, cetyl
pyridinium chloride, farnesol (3,7,ll-trimethyl-2,6,10-dodecatrien-l-ol), N-(4-chlorophenyl)-N'- (3,4-dichlorophenyl)urea (Triclocarban), silver halides, octoxyglycerin (Sensiva™ SC 50) and various zinc salts (for example, zinc ricinoleate), bactericides, bacteriostats, or the like, or combinations thereof. The deodorant active may be present in an amount of from about 0 weight% to about 10 weight %, based on a total weight of the composition.
Base
[40] As used herein, the term “base” may refer to or encompass all other materials in the composition that are not the antiperspirant active and/or the fatty alcohols. The base may provide or be capable of or configured to provide the form of the composition. As discussed above, the composition may be in the form of an aqueous liquid, a gel, an aerosol, or a cream. In at least one implementation, the composition is a solid stick or soft solid at ambient room temperature (e.g., about 25 °C). The stick form is an example of a solid form, and the soft solid is a thickened form that may or may not be solid. The stick form may be distinguished from a soft solid in that, in a stick, the formulated product may retain its shape for extended time periods outside the package, the product not losing its shape significantly (allowing for some shrinkage due to solvent evaporation). Adjustment of amounts of gelling or thickening agents may be used in order to form a soft solid or stick.
[41] The compression force of a stick product may be greater than 3000 g. For example, the compression force of a stick product may be greater than 3000 g, greater than 4000 g, greater than 4500 g, greater than 5000 g, greater than 6000 g, greater than 7000 g, greater than 8000 g, or greater than 9000 g. In another implementation, the compression force may be from about 3500 g to about 10,000 g.
Gelling Agents
[42] The composition may include one more gelling agents. Illustrative gelling agents may be or include, but are not limited to, waxes, esters of fatty acid and fatty alcohol, triglycerides, partially or fully hydrogenated soybean oil, partially or fully hydrogenated castor oil, other partial or fully hydrogenated plant oils, stearyl alcohol, other cosmetically acceptable materials, which are solid or semi solid at room temperature and provide a consistency suitable for application to the skin, or the like, or any combination thereof.
[43] In at least one implementation, the gelling agent may include a combination of hydrogenated soybean oil and a hydrocarbon of the formula CnFhn+2, wherein n is 20 to 100, and
the hydrocarbon is at least 90% linear. The fully or partially hydrogenated soybean oil may be or include those described in U.S. Patent Application Publication Nos. 2008/0187504A1 and 2008/0187503A1. The hydrogenated soybean oil from U.S. Patent Application Publication No. 2008/0187504A1 is almost, but not fully hydrogenated. The amount of hydrogenation is measured by the iodine value. The iodine value may be measured by ASTM D5554-95 (2006). The iodine value of the hydrogenated soybean oil used herein is greater than 0 to 20. The iodine value may be 1 to 5. The partially hydrogenated soybean oil from U.S. Patent Application Publication No. 2008/0187503A1 may have a melting point that of about -15°C (5°F) to 38°C (100°F). The melting point may alternatively be 26°C (80°F) to 38°C (100°F). To obtain the desired melting point, the oil may be partially hydrogenated or a blend of non-hydrogenated with partially or fully hydrogenated oils and/or waxes.
[44] The partially or fully hydrogenated soybean oil may be present in an amount of from greater than 0 weight % to about 20 weight %, based on a total weight of the composition. In another example, the partially or fully hydrogenated soybean oil may be present in an amount of from greater than 0 to about 10 weight %, based on a total weight of the composition. In yet another example, the partially or fully hydrogenated soybean oil may be in an amount of at least 1 weight %, 2 weight %, 3 weight %, 4 weight %, 5 weight %, 6 weight %, 7 weight %, 8 weight %, or 9 weight %, based on the total weight of the composition. In another example, the amount may be present in an amount of less than 10 weight %, 9 weight %, 8 weight %, 7 weight %, 6 weight %, 5 weight %, 4 weight %, 3 weight %, 2 weight %, 1 weight %, based on a total weight of the composition.
[45] As discussed above, the hydrocarbon may be a hydrocarbon of the formula CnFhn+2, where n is 20-100, and where the hydrocarbon may be at least 90% linear. In one example, the hydrocarbon may be or include a paraffin. In another example, the hydrocarbon may be or include polyethylene/polymethylene. The polyethylene may have a weight average molecular weight of from about 300 kDa to 3000 kDa. The polyethylene may have a melting point of from about 50°C to about 129°C.
Volatile Silicone
[46] The composition may include one or more volatile silicones. The volatile silicone may be a volatile cyclic polydimethylsiloxane (cyclomethicone), e.g., cyclopentasiloxane. As used herein, the term volatile material or volatile silicone may refer to a material or silicone, respectively, that
has a measurable vapor pressure at ambient temperature. Preferably, the volatile cyclic polydimethylsiloxane is cyclomethicone. Various types of cyclomethicones may be used. Illustratively, and not by way of limitation, the volatile silicones are one or more members selected from cyclic polydimethylsiloxanes such as those represented by Formula (I):
Formula (I) where n may be an integer with a value of from 3 to 7, particularly from 5 to 6. Illustrative cyclomethicones may be or include, but are not limited to, DC-345 and DC-245, manufactured by Dow Coming Corporation of Midland, MI. These types of cyclomethicones may include a tetramer (octylmethylcyclotetrasiloxane) and/or a pentamer (decamethylcyclopentasiloxane). The amount of any one or more of the volatile silicones present in the composition may be from about 5 weight % to about 70 weight %, based on a total weight of the composition. For example, the volatile silicones may be present in an amount of from about 25 weight % to about 45 weight %, based on a total weight of the composition.
[47] The composition may include one or more ionizable inorganic salts. The ionizable salts may be in the form MaXb where a=l, or 2 and b=l or 2; M may be Na+1, Li+1, K+1, Mg+2, Ca+2, Sr+2, and Zn+2, and X may be chloride, bromide, iodide, citrate, gluconate, lactate, glycinate, glutamate, ascorbate, aspartate, nitrate, phosphate, hydrogenphosphate, dihydrogenphosphate, formate, maloneate, maleate, succinate, carbonate, bicarbonate, sulfate, and hydrogensulfate. In some implementations, the salts are chosen from NaCl and ZnCh. As will be appreciated by those skilled in the art, while it may be possible under certain circumstances to add a salt directly to a portion of the mixture during manufacturing, it is desired to add the salt as a mixture or solution of the salt in a carrier or solvent, particularly water.
[48] The composition may include one or more particulates. Illustrative particulates may be or include, but are not limited to, talc, mica, fragrance encapsulates, or hydrophobically modified starches, such as aluminum starch octenyl succinate (MACKADERM™ ASTRO-DRY™ commercially available from McIntyre Group Ltd. of University Park, IL). If the composition is in a liquid form and dispensed through a roll-on applicator, the average particle size of the
suspended material is sized so that it may pass through the application to prevent the ball applicator from malfunctioning. Usually, the average particle size does not exceed 150 microns.
[49] The composition may include one or more optional ingredients, such as a malodor counteracting alpha, beta-unsaturated ester or mixtures of such materials. The level of the malodor counteracting composition to deliver a perceivable odor control benefit when delivered from an antiperspirant and/or deodorant composition may be from about 0.05 weight % to about 0.45 weight %, based on a total weight of the composition. The alpha, beta-unsaturated ester malodor counteracting materials may be incorporated within the oil phase of the composition. Example of these malodor counteracting components may be found in U.S. Pat. No. 6,610,648 and U.S. Pat. No. 6,495,097, the contents of which are incorporated herein only for their disclosure of the alpha, beta unsaturated esters. Examples of the alpha, beta unsaturated ester may be found in WO 2005/025523, which was filed in the U.S. as U.S. application Ser. No. 10/571,488, both of which are incorporated herein by reference to the extent that they do not conflict with the present disclosure.
[50] Illustrative alpha, beta unsaturated esters may be or include, but are not limited to: (1) 3- phenyl-2-propenoic acid alkyl esters wherein R1 is a substituent on the benzene ring and is chosen from an alkyl, an alkoxy, an aryl, or a substituted aryl. In certain embodiments, R1 is chosen from H, a Ci to Cs alkyl, a Ci to Cs alkoxy, or an aryl; and R2 is a subsistent group replacing the carboxylic acid hydrogen to form the ester where R2has greater than 6 carbon atoms, an aryl, or a substituted aryl group, in certain embodiments R2 is a Cr, to C12 alkyl or is a benzyl group; and (2) an ester of fumaric or maleic acid having linear ester carbon chains from 3-9 carbons, for example dihexyl fumarate; (3) e-phenyl propenoic acid ester chosen from octyl methoxy cinnamate, phenylethyl cinnamate, benzyl cinnamate; (4) an aliphatic unsaturated ester, such as dihexyl fumarate.
[51] The composition may optionally include one or more absorbent materials. Illustrative absorbent materials may be or include, but are not limited to, corn starch, talc, clay, sodium polyacrylate, cotton fiber, fragrances, or the like, or combinations thereof.
[52] When water is present, for example in a liquid roll-on composition, the water may make up the balance of the composition. In at least one implementation, the composition may include water in an amount of at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 85%, based on a total weight of the composition.
[53] As used herein, the “total solids of the composition” may refer to the amount of non-volatile materials in the composition. The percent solids is measured by a CEM Smart System moisture/solids analyzer which uses microwave energy to dry the samples. In one implementation, the total solids of the composition may be less than 30%, less than 25%, less than 20%, or less than 15%.
[54] In aerosol form, any known and/or suitable aerosol propellant may be used.
[55] The composition may include one or more antioxidants. Illustrative antioxidants may be or include, but are not limited to, butylated hydroxytoluene (BHT), pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate (Tinogard TT™ from Ciba/BASF), caffeine, and abies picea extract (GranLux™ AOX-G4 from Granula, which is a spruce knot extract in butylenes glycol).
[56] The composition may include one or more emollients. The emollients may be present in an amount effective to achieve a desired emollient effect. It should be appreciated that emollients are known in the art and are used to impart a soothing effect on the skin.
[57] Non-volatile emollients are preferable in the present invention. Classes of non-volatile emollients include non-silicone and silicone emollients. Non-volatile, non-silicone emollients include C 12-15 alkyl benzoate. The non-volatile silicone material may be a polyethersiloxane, polyalkyarylsiloxane or polyethersiloxane copolymer. An illustrative non-volatile silicone material may be or include, but is not limited to, phenyl trimethicone. Non-limiting examples of emollients may be found in U.S. Pat. No. 6,007,799. Illustrative emollients may be or include, but is not limited to, PPG- 14 butyl ether, PPG-3 myristyl ether, stearyl alcohol, stearic acid, glyceryl monoricinoleate, isobutyl palmitate, glyceryl monostearate, isocetyl stearate, sulphated tallow, oleyl alcohol, propylene glycol, isopropyl laurate, mink oil, sorbitan stearate, cetyl alcohol, hydrogenated castor oil, stearyl stearate, hydrogenated soy glycerides, isopropyl isostearate, hexyl laurate, dimethyl brassylate, decyl oleate, diisopropyl adipate, n-dibutyl sebacate, diisopropyl sebacate, 2-ethyl hexyl palmitate, isononyl isononanoate, isodecyl isononanoate, isotridecyl isononanoate, 2-ethyl hexyl palmitate, 2-ethyl hexyl stearate, Di-(2-ethyl hexyl)adipate), Dim ethyl hexyl)succinate, isopropyl myristate, isopropyl palmitate, isopropyl stearate, octacosanol, butyl stearate, glyceryl monostearate, polyethylene glycols, oleic acid, triethylene glycol, lanolin, castor oil, acetylated lanolin alcohols, acetylated lanolin, petrolatum, isopropyl ester of lanolin, fatty acids, mineral oils, butyl myristate, isostearic acid, palmitic acid, PEG-23 oleyl ether, olelyl oleate, isopropyl linoleate, cetyl lactate, lauryl lactate, myristyl lactate, quatemised hydroxy alkyl,
aminogluconate, vegetable oils, isodecyl oleate, isostearyl neopentanoate, myristyl myristate, oleyl ethoxy myristate, diglycol stearate, ethylene glycol monostearate, myristyl stearate, isopropyl lanolate, paraffin waxes, glycyrrhizic acid, hydrocyethyl stearate amide, or the like, or combinations thereof.
[58] In at least one implementation, the one or more emollients may be or include, but are not limited to, linear silicones, cyclic silicones, hydrocarbons, polyhydroxy alcohols having more than 3 carbon atoms, liquid or solid polyalkyleneglycol ethers containing a polypropylene glycol (PPG) moiety and terminating in an alkyl ether, or the like, or combinations thereof. In another implementation, the emollient may be a volatile silicone, as discussed above, having a flash point of 100° C. or less, such as cyclomethicone, cyclopentasiloxane, or trisiloxane.
Surfactant
[59] The compositions may include one or more surfactants. The one or more surfactants may be present in an amount of from greater than 0 weight % to about 20 weight %, based on a total weight of the composition. The one or more surfactants may be or include, but are not limited to anionic surfactants, cationic surfactants, amphoteric or zwitterionic surfactants, nonionic surfactants, silicone surfactants, or combinations thereof.
[60] Illustrative nonionic surfactants may be or include, but are not limited to, (a) sorbitan esters and ethoxylated sorbitan esters (for example PEG-20 sorbitan isostearate, sorbitan monolaurate, polysorbate-20, polysorbate-40, polysorbate-60, polysorbate-80); (b) ethoxylates (for example, Ceteth-20, PEG-30 castor oil. PEG-40 hydrogenated castor oil, PEG-60 hydrogenated castor oil. Laureth-7, Isolaureth-6, Steareth-10. Steareth-20. Steareth-21, Steareth-100. Ceteareth-12, Oleth- 5, Oleth-10); (c) ethoxylated adducts (for example, PEG-25 stearate, glyceryl stearate and PEG- 100 stearate): (d) PEG esters (for example, PEG-8 oleate, PEG-8 laurate, PEG-8 dilaurate. PEG- 12 dilaurate, PEG-80 diisostearate, PEG-40 stearate); (e) propoxylates (for example, PPG-10 butanediol, PPG-50 oleyl ether, PPG-2-ceteareth-9, PPG-3-deceth-3. PPG-5-ceteth-20); (f) ethoxylated modified triglycerides (for example, PEG-20 com glycerides. PEG- 12 palm kernel glycerides); (g) alkylphenol aromatic ethoxylates (for example, dinonylphenol ethoxylate with 9 moles of EO, octylphenol ethoxylate with 20 moles of EO, octylphenol ethoxylate with 40 moles of EO): (h) block copolymers that are alkoxylated glycols having ethoxylated and propoxylated segments (for example, POLOXAMER™ 182 and 234. POLOXAMER™ 105 Benzoate, and MEROXAPOL™ 174); or the like, or combinations thereof. In one implementation, the nonionic
surfactant includes ethoxylated nonionic surfactants and propoxylated non-ionic surfactants. Example of these include, but are not limited to, Steareth 2, Steareth 20, and Steareth 21. In an oil in water composition, a combination of two surfactants, one having an HLB value of 2 to 8 (such as Steareth 2) and the other having an HLB of 9 to 18 (such as Steareth 20 and 21), may be used. In one implementation, the nonionic surfactant is selected such that it has an HLB (hydrophilic- lipophilic balance) value of from about 8 to about 16 or from about 8 to about 12.
[61] Examples of silicone surfactants may be found in U.S. Pat. No. 6,485,716, which is incorporated herein by reference only for the listing of the silicone surfactants. Illustrative silicone surfactants may be or include, but are not limited to, silicone polyglucosides (for example, octyl dimethicone ethoxy glucoside) and silicone copolyols having an HLB (hydrophilic lipophilic balance) value of less than 8. The HLB value may be measured in a variety of ways such as described in conventional references or found listed in tables of data recording such values. It is intended that any type of HLB measurement technique may be used.
[62] The silicone copolyols may include, but are not limited to, copolyols of the following Lormula (II) and (III). Lormula (II) materials may be represented by: (R10)3SiO[(R11)2SiO]xSi(R12)(RbO((C2H4O))p(C3H6O)s(Rc)O]ySi(R13) wherein each of R10, R11, R12, and R13 may be the same or different and each is chosen from C1-C6 alkyl; Rb is the radical — CmH2m — ; Rc is a terminating radical which may be hydrogen, an alkyl group of one to six carbon atoms, an ester group such as acyl, or an aryl group such as phenyl; m has a value of two to eight: p and s have values such that the oxyalkylene segment — (C2H40)P — (C3H.60).s — has a molecular weight in the range of 200 to 5,000; the segment preferably having 50 to 100 mole percent of oxyethylene units — ((C2H40)P — and 1 to 50 mole percent of oxypropylene units — (C3H60).s — ; x has a value of 8 to 400; and y has a value of 2 to 40. Preferably each of R10, R11, R12, and R13 is a methyl group; Rc is H; m is preferably three or four whereby the group Rb is most preferably the radical — (C¾)3 — ; and the values of p and s are such as to provide a molecular weight of the oxyalkylene segment — (C2H40)P — (C3H60)S — of between 1,000 to 3.000. In one embodiment, p and s should each have a value of 18 to 28. In a preferred implementation, the silicone copolyol is dimethicone copolyol. A second siloxane polyether (copolyol) may have the Lormula (III): (R10)3SiO[(Ru)2SiO]xSi(R12)(RbO(C2H4O)pRc)O]ySi(R13)3 wherein p has a value of 6 to 16; x has a value of 6 to 100; and y has a value of 1 to 20 and the other moieties have the same definition as defined in Lormula (II).
[63] It should be understood that in both Formulas (II) and (III) shown above, that the siloxane- oxyalkylene copolymers may, in alternate embodiments, take the form of end-blocked polyethers in which the linking group Rb, the oxyalkylene segments, and the terminating radical R occupy positions bonded to the ends of the siloxane chain, rather than being bonded to a silicon atom in the siloxane chain. Thus, one or more of the R10, R11, R12, and R13 substituents that are attached to the two terminal silicon atoms at the end of the siloxane chain may be substituted with the segment — Rb— O— (C2H40)p— (C3H60)S— RC or with the segment — Rb— O— (C2H40)— Rc. In some instances, it may be desirable to provide the segment — Rb — O — (C2H40)P — (C3H60)S — Rcor the segment — Rb — O — (C2H40)P — Rc at locations which are in the siloxane chain as well as at locations at one or both of the siloxane chain ends.
[64] Examples of suitable dimethicone copolyols are available either commercially or experimentally from a variety of suppliers including Dow Coming Corporation, Midland, MI; General Electric Company, Waterford, NY; Witco Corp., Greenwich, CT; and Goldschmidt Chemical Corporation, Hopewell, VA. Examples of products include DOW CORNING 5225C from Dow Corning, which is a 10% dimethicone copolyol in cyclomethicone; DOW CORNING 2-5185C, which is a 45-49% dimethicone copolyol in cyclomethicone; SILWET L-7622 from Witco; ABIL3 EM97 from Goldschmidt, which is an 85% dimethicone copolyol in D5 cyclomethicone; and various dimethicone copolyols available either commercially or in the literature.
[65] It should also be noted that various concentrations of the dimethicone copolyols in cyclomethicone may be used. While a concentration of 10 weight % in cyclomethicone may often be seen commercially, other concentrations may be made by stripping off the cyclomethicone or adding additional cyclomethicone. The higher concentration materials such as DOW CORNING 2-5185 may be used in at least one implementation. In a preferred example, the silicone copolyol may be present in an amount of from about 0.5 weight % to about 5 weight %, or about 1 weight % to about 2 weight %, based on a total weight of the composition.
[66] Illustrative anionic surfactants may also be or include, but are not limited to, sodium lauryl sulfate, sodium cocoyl monoglyceride sulfonate, sodium lauryl sarcosinate, sodium lauryl isoethionate, sodium laureth carboxylate, and sodium dodecyl benzenesulfonate.
[67] Examples of zwitterionic surfactants include those which may be broadly described as derivatives of aliphatic quaternary ammonium, phosphonium, and sulfonium compounds, in which
the aliphatic radicals may be straight chain or branched and wherein one of the aliphatic substituents contains from about 8 to 18 carbon atoms and one contains an anionic water- solubilizing group, e.g., carboxy, sulfonate, sulfate, phosphate, or phosphonate. Illustrative zwitterionic surfactants may be or include, but are not limited to 4-[N,N-di(2-hydroxyethyl)-N- octadecylammonio] -butane- 1 -carboxylate; 5 - [S -3 -hydroxypropyl-S -hexadecylsulfonio] -3 - hydroxypentane-l-sulfate; 3-[P,P-P-diethyl-P-3,6,9trioxatetradecyl-phosphonio]-2- hydroxypropane- 1 -phosphate; 3-[N,N-dipropyl-N-3dodecoxy-2-hydroxypropylammonio]- propane- 1 -phosphonate; 3 -(N,N-di-methy-N -hexadecylammonio)propane- 1 - sulfonate; 3 -(N,N- dimethyl-N-hexadecylammonio)-2-hydroxypropane-l-sulfonate; 4-(N,N-di(2-hydroxyethyl)-N- (2-hydroxydodecyl)ammonio] -butane- 1 -carboxylate; 3 - [S -ethyl-S -(3 -dodecoxy-2- hydroxypropyl)sulfonio] -propane- 1 -phosphate; 3-(P,P-dimethyl-P-dodecylphosphonio)propane- 1 -phosphonate; 5 - [N,N-di(3 -hydroxypropyl)-N -hexadecylammonio] -2-hydroxy-pentane- 1 - sulfate, or the like, or combinations thereof.
[68] Examples of amphoteric surfactants include those which may be broadly described as derivatives of aliphatic secondary and tertiary amines in which the aliphatic radical may be straight chain or branched and wherein one of the aliphatic substituents contains from 8 to 18 carbon atoms and one contains an anionic water solubilizing group, e.g., carboxy, sulfonate, sulfate, phosphate, or phosphonate. Examples of compounds falling within this definition are sodium 3- dodecylaminopropionate and sodium 3-dodecylaminopropane sulfonate. Further amphoteric surfactants are described in U.S. Pat. No. 2,658,072, U.S. Pat. No. 2,438,091 and U.S. Pat. No. 2,528,378.
[69] The preferred amphoteric surfactants are betaines. Illustrative betaines useful herein may be or include, but are not limited to, the high alkyl betaines such as coco dimethyl carboxymethyl betaine, lauryl dimethyl carboxy-methyl betaine, lauryl dimethyl alpha-carboxyethyl betaine, cetyl dimethyl carboxymethyl betaine, lauryl bis-(2-hydroxyethyl) carboxy methyl betaine, stearyl bis- (2-hydroxypropyl)carboxymethyl betaine, oleyl dimethyl gamma-carboxypropyl betaine, lauryl bis-(2-hydroxypropyl) alpha-carboxyethyl betaine, or the like, or combinations thereof. The sulfobetaines may be represented by coco dimethyl sulfopropyl betaine, stearyl dimethyl sulfopropyl betaine, amido betaines, amidosulfobetaines, or the like.
[70] The compositions as disclosed herein are described and claimed with reference to their ingredients, as is usual in the art. As would be evident to one skilled in the art, ingredients may in
some instances react with one another such that the true composition of the final formulation may not correspond exactly to the ingredients listed. As such, in some examples, it should be understood that the disclosure may extend to the product of the combination of the listed ingredients.
[71] The compositions of the present disclosure may be manufactured using methods known in the art. Generally, the ingredients are combined and heated to melt the components (other than inert filler), and the melted components (together with particulate inert filler) are mixed. Desirably, volatile materials, such as the fragrance materials, are incorporated in the composition in the latter stages of the mixing cycle, in order to avoid volatilization thereof. After mixing, the molten composition may be poured directly into the dispensers, after which the compositions harden into a solid, and the container is capped to preserve the product until use.
[72] As discussed above, the compositions disclosed herein may be applied to the skin of mammals. In an exemplary implementation, the compositions disclosed herein may be applied to the skin in the axillary area of a human.
METHODS
[73] The present disclosure may provide methods for treating, inhibiting, and/or reducing the growth of undesirable odor-causing bacteria on skin. For example, the present disclosure may provide methods for treating, inhibiting, and/or reducing the growth of Corynebacterium. The method may include applying or contacting any one of the compositions disclosed herein to the skin of the mammal. The method may also include applying or contacting any one of the compositions disclosed herein to the skin in the axillary area of the mammal. The method may also include administering any one of the compositions disclosed herein to the mammal in an amount effective to treat, inhibit, and/or reduce the growth of detrimental bacteria. The method may include applying or contacting any one of the compositions disclosed herein to the skin of the mammal at least once a day, at least two times a day, at least three times a day, or more. The method may include maintaining contact of the compositions disclosed herein to the skin for at least 1 hour, at least 3 hours, at least 5 hours, at least 10 hours, at least 15 hours, or at least 18 hours. The method may include applying or contacting any one of the compositions disclosed herein to the skin daily for at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5
days, at least 6 days, at least 1 week, at least 2 weeks, at least 3 weeks, at least 4 weeks, at least 5 weeks, or more.
[74] The present disclosure may also provide methods for reducing odor producing bacteria on skin. For example, the present disclosure may provide methods for treating, inhibiting, and/or reducing the amount of Corynebacterium on skin. The method may include applying or contacting any one of the compositions disclosed herein to the skin of the mammal. The method may also include applying or contacting any one of the compositions disclosed herein to the skin in the axillary area of the mammal. The method may also include administering any one of the compositions disclosed herein to the mammal in an amount effective to treat, inhibit, and/or reduce the amount of detrimental bacteria. The method may include applying or contacting any one of the compositions disclosed herein to the skin of the mammal at least once a day, at least two times a day, at least three times a day, or more. The method may include maintaining contact of the compositions disclosed herein to the skin for at least 1 hour, at least 3 hours, at least 5 hours, at least 10 hours, at least 15 hours, or at least 18 hours. The method may include applying or contacting any one of the compositions disclosed herein to the skin daily for at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 1 week, at least 2 weeks, at least 3 weeks, at least 4 weeks, at least 5 weeks, or more.
[75] The present disclosure may also provide methods for promoting the growth of beneficial bacteria on skin. For example, the present disclosure may provide methods for promoting the growth of Staphylococcus bacteria. The method may include applying or contacting any one of the compositions disclosed herein to the skin of the mammal. The method may also include applying or contacting any one of the compositions disclosed herein to the skin in the axillary area of the mammal. The method may also include administering any one of the compositions disclosed herein to the mammal in an amount effective to promote the growth of beneficial bacteria. The method may include applying or contacting any one of the compositions disclosed herein to the skin of the mammal at least once a day, at least two times a day, at least three times a day, or more. The method may include maintaining contact of the compositions disclosed herein to the skin for at least 1 hour, at least 3 hours, at least 5 hours, at least 10 hours, at least 15 hours, or at least 18 hours. The method may include applying or contacting any one of the compositions disclosed herein to the skin daily for at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5
days, at least 6 days, at least 1 week, at least 2 weeks, at least 3 weeks, at least 4 weeks, at least 5 weeks, or more.
[76] The present disclosure may also provide methods for producing or enhancing the production of antimicrobial peptides on the skin. For example, the present disclosure may provide methods for promoting the growth of Staphylococcus bacteria, which produce antimicrobial peptides. The method may include applying or contacting any one of the compositions disclosed herein to the skin of the mammal to promote the growth of Staphylococcus bacteria. The method may also include applying or contacting any one of the compositions disclosed herein to the skin in the axillary area of the mammal. The method may also include administering any one of the compositions disclosed herein to the mammal in an amount effective to promote the growth of beneficial bacteria. The method may include applying or contacting any one of the compositions disclosed herein to the skin of the mammal at least once a day, at least two times a day, at least three times a day, or more. The method may include maintaining contact of the compositions disclosed herein to the skin for at least 1 hour, at least 3 hours, at least 5 hours, at least 10 hours, at least 15 hours, or at least 18 hours. The method may include applying or contacting any one of the compositions disclosed herein to the skin daily for at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 1 week, at least 2 weeks, at least 3 weeks, at least 4 weeks, at least 5 weeks, or more.
[77] The present disclosure may also provide methods for providing, enhancing, or otherwise increasing a barrier on skin against the colonization of potentially pathogenic microbes. For example, the present disclosure may provide methods for promoting the growth of Staphylococcus bacteria, which provides or enhances the barrier against pathogenic microbes. The method may include applying or contacting any one of the compositions disclosed herein to the skin of the mammal to promote the growth of Staphylococcus bacteria. The method may also include applying or contacting any one of the compositions disclosed herein to the skin in the axillary area of the mammal. The method may also include administering any one of the compositions disclosed herein to the mammal in an amount effective to promote the growth of beneficial bacteria. The method may include applying or contacting any one of the compositions disclosed herein to the skin of the mammal at least once a day, at least two times a day, at least three times a day, or more. The method may include maintaining contact of the compositions disclosed herein to the skin for at least 1 hour, at least 3 hours, at least 5 hours, at least 10 hours, at least 15 hours, or at least 18
hours. The method may include applying or contacting any one of the compositions disclosed herein to the skin daily for at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 1 week, at least 2 weeks, at least 3 weeks, at least 4 weeks, at least 5 weeks, or more.
[78] The present disclosure may provide methods for selectively treating, increasing, decreasing, promoting the growth of, and/or inhibiting the growth of one or more Gram-positive bacteria. Illustrative Gram-positive bacteria may be or include, but are not limited to, bacteria of the genera Listeria, Staphylococcus, Streptococcus, Bacillus, Corynebacterium, Enterococcus, Peptostreptococcus, Clostridium, or the like, or combinations thereof. Illustrative species may be or include, but are not limited to, Listeria monocytogenes, Staphylococcus aureus (including methicillin-resistant S. aureus, or MRSA), Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus pneumoniae, Bacillus cereus, Staphylococcus haemolyticus, Staphylococcus epidermidis, Corynebacterium striatum, Bacillus anthracia, Clostridium botulinum, Clostridium perfringens, Clostridium difficile, Clostridium tetani, Corynebacterium diphtheriae, Corynebacterium ulcerans, Enterococcus faecium (including vancomycin-resistant E. faecium, or VRE), Peptostreptococcus anaerobius, or the like, or combinations thereof. The methods may include selectively treating, increasing, decreasing, promoting the growth of, and/or inhibiting the growth of one or more Gram-positive bacteria on skin in mammals. The method may include selectively increasing or promoting the growth of beneficial bacteria, such as Staphylococcus, while inhibiting or reducing the growth of detrimental bacteria, such as Corynebacterium. The method may include applying or contacting any one of the compositions disclosed herein to the skin of the mammal. The method may also include applying or contacting any one of the compositions disclosed herein to the skin in the axillary area of the mammal. The method may also include administering any one of the compositions disclosed herein to the mammal in an amount effective to selectively treat, decrease, promote the growth of, and/or inhibit the growth of one or more Gram-positive bacteria. The method may include applying or contacting any one of the compositions disclosed herein to the skin of the mammal at least once a day, at least two times a day, at least three times a day, or more. The method may include maintaining contact of the compositions disclosed herein to the skin for at least 1 hour, at least 3 hours, at least 5 hours, at least 10 hours, at least 15 hours, or at least 18 hours. The method may include applying or contacting any one of the compositions disclosed herein to the skin daily for at least 1 day, at least
2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 1 week, at least 2 weeks, at least 3 weeks, at least 4 weeks, at least 5 weeks, or more.
[79] The present disclosure may provide a composition for use in treating, inhibiting, and/or reducing the growth of detrimental bacteria on skin. The composition may include a base, an antiperspirant and/or a deodorant active, one or more fatty alcohols (e.g., 2-butyl- 1-octanol), or combinations thereof.
[80] The present disclosure may provide a composition for use in reducing odor producing bacteria on skin. The composition may include a base, an antiperspirant and/or a deodorant active, one or more fatty alcohols (e.g., 2-butyl- 1-octanol), or combinations thereof.
[81] The present disclosure may provide a composition for use in promoting the growth of beneficial bacteria on skin. The composition may include a base, an antiperspirant and/or a deodorant active, one or more fatty alcohols (e.g., 2-butyl- 1-octanol), or combinations thereof.
[82] The present disclosure may provide a composition for use in producing or enhancing the production of antimicrobial peptides on the skin. The composition may include a base, an antiperspirant and/or a deodorant active, one or more fatty alcohols (e.g., 2-butyl- 1-octanol), or combinations thereof.
[83] The present disclosure may provide a composition for use in providing, enhancing, or otherwise increasing a barrier on skin against the colonization of potentially pathogenic microbes. The composition may include a base, an antiperspirant and/or a deodorant active, one or more fatty alcohols (e.g., 2-butyl- 1-octanol), or combinations thereof.
[84] As used herein, the expression or term “treating, inhibiting, and/or reducing bacterial growth” or similar expressions may refer to inhibition of the growth and/or reduction in the number of bacteria on a substrate (e.g., skin). Further, as used herein, the expression or term “promoting the growth of bacteria” or similar expressions may refer to the enhancement or increase in the rate of the growth of the bacteria without intervention, and/or increase in the number of bacteria on a substrate. The increase or decrease in the bacteria may be more than expected without intervention with the methods and/or compositions disclosed herein.
[85] It should be appreciated that while implementations disclosed herein are generally directed to the treatment of humans, the compositions and methods disclosed herein may be equally applied to and performed on animal subjects, particularly mammalian subjects (e.g., mice, rats, dogs, cats,
rabbits, horses, etc.), avian subjects (e.g., parrots, geese, quail, pheasant, etc.), livestock (e.g., pigs, sheep, goats, cows, chickens, turkey, duck, ostrich, emu, etc.), reptile and amphibian subjects.
[86] All ingredients for use in the compositions described herein should be topically acceptable. As used herein, “topically acceptable” may refer to any ingredient that is present in a composition as described in an amount and form which does not render the composition unsafe for use on surfaces of skin.
EXAMPLES
[87] The examples and other implementations described herein are exemplary and not intended to be limiting in describing the full scope of compositions and methods of this disclosure. Equivalent changes, modifications and variations of specific implementations, materials, compositions and methods may be made within the scope of the present disclosure, with substantially similar results.
[88] Example 1
[89] The efficacy of 2-butyl octanol for selectively promoting, inhibiting, reducing, and/or treating bacterial growth was evaluated. Particularly, the efficacy of 2-butyl octanol for selectively promoting, inhibiting, reducing, and/or treating bacterial growth of Corynebacterium and Staphylococcus was evaluated. To evaluate the efficacy, an active solution was prepared by emulsifying 2-butyl octanol with a nonionic surfactant, namely, Polysorbate 80. The active solution included the 2-butyl octanol and the Polysorbate 80 in a ratio of about 83:17. Both positive controls (including no active solution) and negative controls (including no bacteria) were also prepared.
[90] A 96-well plate was utilized to evaluate the growth of the respective bacteria at varying dilutions. Each of the wells of a 96-well plate was aseptically filled with about 100 pL of Tryptic Soy Broth (TSB). In the first well of each row, about 100 pL of either the active solution (including the 2-butyl octanol and Polysorbate 80) or the desired solvent for the respective positive and negative controls was added to thereby provide a total of about 200 pL in the first well of the each respective row. A multi-channel pipette was then utilized to prepare a two-fold dilution in each column. Specifically, a multi-channel pipette set to about 100 pL was utilized to mix and transfer about 100 pL of the 200 pL from the wells of the first column to the respective wells of a subsequent column. This was repeated for each of the remaining eleven columns. About 100 pL
of the twelfth column was removed, thereby leaving about 100 pL in each of the 96 wells. For the negative control well, about 100 pL of a solvent that does not promote bacterial growth was added. Specifically, a phosphate buffered saline (PBS) was utilized for the negative control. About 100 pL of the respective bacteria adjusted to 0.1 optical density (OD) bacteria was added to all other wells. The well plate was then incubated overnight at about 37°C in a growth inhibition assay machine. Measurements were taken at about one hour increments. The results of the analysis are summarized in Tables 1-3.
Table 1
Measured Optical Density of S. Haemolyticus with 2-Butyl Octanol
Table 2
Measured Optical Density of S. Epidermidis with 2-Butyl Octanol
Table 3
Measured Optical Density of C. Striatum with 2-Butyl Octanol
[91] As indicated in Tables 1-3, the 2-butyl octanol selectively or preferably inhibited the bacterial growth of Corynebacterium and promoted the growth of Staphylococcus. Specifically, the presence of 2-butyl octanol, surprisingly and unexpectedly, did not inhibit the growth of and/or promoted the growth of S. epidermidis and S. hominis when present in an amount of about 0.02 weight % to about 5.2 weight %. Conversely, when 2-butyl octanol was present in an amount of at least about 1.6% or greater the growth of C. stratium was completely inhibited (Table 3). It should be appreciated that amounts of 2-butyl octanol greater than about 5.2 weight % were not measured as the system because too turbid to be measured.
[92] Example 2
[93] The efficacy of 2-butyl octanol in a personal care composition for selectively promoting, inhibiting, reducing, and/or treating bacterial growth was evaluated. Particularly, a control or base deodorant composition (1) and a test deodorant composition including 2-butyl octanol were prepared by combining the ingredients/components according to Table 4. The control (1) and test (2) deodorant compositions were evaluated in an in-house panel study with 11 subjects. Each of the subjects used the control (1) and test (2) deodorant compositions once daily for four weeks.
Specifically, each of the subjects used the control deodorant composition (1) in one underarm and the test deodorant composition (2) in the other underarm. After four weeks of daily usage, samples were collected from the underarm and bacteria genomic analysis (16S rRNA sequencing) was performed on these samples. The results of the evaluation are summarized in Table 5.
Table 4
Control (1) and Test (2) Deodorant Compositions Weight (%)
Table 5
Relative Abundance of Bacteria (%)
Before and After Treatment with Control (1) and Test (2) Deodorant Compositions
[94] As indicated in Table 5, the test deodorant composition (2) including the 2-butyl octanol surprisingly and unexpectedly exhibited a significant reduction in the relative abundance of Corynebacteria from about 42% to about 13% (p=0.004) and increased the relative abundance of Staphylococcus from about 36% to about 59% (p=0.02). The results are both surprising and unexpected, as the control deodorant composition (1) decreased the relative abundances of both the Corynebacteria and Staphylococcus bacteria.
[95] The present disclosure has been described with reference to exemplary implementations. Although a limited number of implementations have been shown and described, it will be appreciated by those skilled in the art that changes may be made in these implementations without departing from the principles and spirit of the preceding detailed description. It is intended that the present disclosure be construed as including all such modifications and alterations insofar as they come within the scope of the appended claims or the equivalents thereof.
Claims (20)
1. A composition comprising: a base and one or more fatty alcohols, wherein the one or more fatty alcohols are present in an amount effective to selectively inhibit the growth of at least one detrimental Gram-positive bacteria and promote the growth of at least one beneficial Gram positive bacteria on skin.
2. The composition of claim 1, wherein the one or more fatty alcohols comprise one or more of 2-prop yl-heptanol, 2-butyl octanol, 2-pentyl- 1-nonanol, 2-hexyl- 1-decanol, 2-heptyl-l- undecanol, 2-octyl- 1-dodecanol, 2-nonyl-l-tridecanol, 2-decyl-tetradecanol, 2-undecyl-l- pentadecanol, 2-dodecyl-hexadecanol, 2-tridecyl-heptadecanol, 2-tetradecyl-l-octadecanol, 2- pentadecyl-l-nonadecanol, 2-hexadecyl-l-eicosanol, 2-heptadecyl-l-heneicosanol, 2-octadecyl- 1-docosanol, 2-nonadecyl-l-tricosanol, 2-eicosyl-tetracosanol, or combinations thereof.
3. The composition of any one of claims 1 and 2, wherein the one or more fatty alcohols comprise 2-butyl octanol.
4. The composition of any one of the foregoing claims, wherein the one or more fatty alcohols is present in an amount of from about 0.01 weight % to about 25 weight %, preferably about 0.01 weight % to about 5 weight %, more preferably, in an amount of at least 0.16 weight % to about 5 weight %, based on a total weight of the composition.
5. The composition of any one of the foregoing claims, wherein the at least one detrimental Gram-positive bacteria comprises Corynebacterium, optionally, Cornebacterium striatum.
6. The composition of any one of the foregoing claims, wherein the at least one beneficial Gram-positive bacteria comprises Staphylococcus, optionally, the Staphylococcus comprises S. epidermidis, S. haemolyticus , or combinations thereof.
7. The composition of any one of the foregoing claims, wherein the composition is a personal care composition, preferably the personal care composition is a cleanser, a lotion, a cream, an emulsion, a shampoo, a conditioner, a shower gel, an antiperspirant, a deodorant, a depilatory, a lipstick, a foundation, a mascara, a sunless tanner, or a sunscreen lotion.
8. The composition of any one of the foregoing claims, wherein the composition further comprises a deodorant active or an antiperspirant active.
9. A method for selectively treating the growth of a detrimental bacteria and promoting the growth of a beneficial bacteria on skin, the method comprising contacting the composition of any one of the foregoing claims with the skin.
10 The method of claim 9, wherein the detrimental bacteria comprises Corynebacterium.
11. The method of claims 9 or 10, wherein the beneficial bacteria comprises Staphylococcus.
12. The method of claims 9 to 11, wherein the composition is contacted with the skin daily for at least one week, at least two weeks, at least three weeks, or at least four weeks.
13. A method for reducing odor producing bacteria on skin, the method comprising contacting the composition of any one of claims 1 to 8 with the skin, optionally, wherein the odor producing bacteria comprises Corynebacterium.
14. The method of claim 13, wherein the composition is contacted with the skin daily for at least one week, at least two weeks, at least three weeks, or at least four weeks.
15. A method for producing or enhancing the production of antimicrobial peptides on skin, the method comprising contacting the composition of any one of claims 1 to 8 with the skin.
16. The method of claim 15, further comprising promoting the growth of Staphylococcus on the skin to thereby produce or enhance the production of the antimicrobial peptides on the skin.
17. The method of claim 15 or 16, wherein the composition is contacted with the skin daily for at least one week, at least two weeks, at least three weeks, or at least four weeks.
18. The composition of any one of claims 1 to 8 for use in treating or inhibiting the growth of a detrimental bacteria on skin, optionally, the detrimental bacteria comprises Corynebacterium.
19. The composition of any one of claims 1 to 8 for use in promoting the growth of a beneficial bacteria on skin, optionally, the beneficial bacteria comprises Staphylococcus.
20. The composition for use according to claim 18 or 19, wherein the composition is contacted with the skin daily for at least one week, at least two weeks, at least three weeks, or at least four weeks.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2019/061522 WO2021096518A1 (en) | 2019-11-14 | 2019-11-14 | Personal care compositions for treating odor causing bacteria and methods for the same |
Publications (3)
Publication Number | Publication Date |
---|---|
AU2019474692A1 AU2019474692A1 (en) | 2022-05-26 |
AU2019474692B2 true AU2019474692B2 (en) | 2023-12-14 |
AU2019474692C1 AU2019474692C1 (en) | 2024-05-09 |
Family
ID=68808608
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2019474692A Active AU2019474692C1 (en) | 2019-11-14 | 2019-11-14 | Personal care compositions for treating odor causing bacteria and methods for the same |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP4021387A1 (en) |
CN (1) | CN114650805A (en) |
AU (1) | AU2019474692C1 (en) |
BR (1) | BR112022008793A2 (en) |
MX (1) | MX2022005497A (en) |
WO (1) | WO2021096518A1 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102004032734A1 (en) * | 2004-03-18 | 2005-10-06 | Henkel Kgaa | Prebiotic substances for deodorants |
EP2353579A1 (en) * | 2010-02-09 | 2011-08-10 | Unilever N.V. | Deodorant composition |
US20180177692A1 (en) * | 2016-12-27 | 2018-06-28 | Colgate-Palmolive Company | Antiperspirant / Deodorant Composition |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2438091A (en) | 1943-09-06 | 1948-03-16 | American Cyanamid Co | Aspartic acid esters and their preparation |
US2528378A (en) | 1947-09-20 | 1950-10-31 | John J Mccabe Jr | Metal salts of substituted quaternary hydroxy cycloimidinic acid metal alcoholates and process for preparation of same |
US2658072A (en) | 1951-05-17 | 1953-11-03 | Monsanto Chemicals | Process of preparing amine sulfonates and products obtained thereof |
DE59509160D1 (en) * | 1995-06-23 | 2001-05-10 | Dalli Werke Waesche & Koerperp | Multi-component preservative for hair and body cleansers |
ZA966814B (en) | 1995-08-18 | 1998-02-12 | Colgate Palmolive Co | Clear cosmetic gel composition. |
DE19643585A1 (en) * | 1996-10-22 | 1998-04-23 | Beiersdorf Ag | Anti-adhesive formulation containing sphingolipid |
AU3510500A (en) | 1999-03-02 | 2000-09-21 | Shaw Mudge & Company | Fragrance and flavor compositions containing odor neutralizing agents |
US6375937B1 (en) | 2000-10-20 | 2002-04-23 | Colgate-Palmolive Company | Antiperspirant salts for enhanced cosmetic products |
US6610648B2 (en) | 2000-12-22 | 2003-08-26 | Givaudan Sa | Malodor counteractant compositions |
US6485716B1 (en) | 2001-10-05 | 2002-11-26 | Colgate-Palmolive Company | High efficacy liquid gel product |
US6960338B2 (en) | 2002-06-28 | 2005-11-01 | Reheis, Inc. | Amino acid free stable aluminum/zirconium antiperspirant solution |
US20040109833A1 (en) | 2002-12-09 | 2004-06-10 | Xiaozhong Tang | High efficacy, low irritation aluminum salts and related products |
US20040198998A1 (en) | 2003-04-04 | 2004-10-07 | Marian Holerca | Glycine-free antiperspirant salts with betaine for enhanced cosmetic products |
US7105691B2 (en) | 2003-06-26 | 2006-09-12 | Colgate-Palmolive Company | Aluminum / zirconium / glycine antiperspirant actives stabilized with Betaine |
US7074394B2 (en) | 2003-07-22 | 2006-07-11 | Reheis, Inc. | Stable aluminum/zirconium antiperspirant solution free of amino acid and polyhydric alcohol |
DE60309027T2 (en) * | 2003-08-26 | 2007-05-10 | Johnson & Johnson Consumer France Sas | Stabilized antiperspirant agent containing soy products |
AR045608A1 (en) | 2003-09-08 | 2005-11-02 | Colgate Palmolive Co | TRANSPARENT GEL ANTITRANSPIRANTE WITH LOW GLYCOL CONTENT |
US7704531B2 (en) | 2005-02-18 | 2010-04-27 | Colgate-Palmolive Company | Enhanced efficacy aluminum or aluminum-zirconium antiperspirant salt compositions containing calcium salt(s) and betaine |
US7976828B2 (en) | 2007-02-02 | 2011-07-12 | Colgate-Palmolive Company | Antiperspirant/deodorant composition |
US9789038B2 (en) | 2007-02-02 | 2017-10-17 | Colgate-Palmolive Company | Antiperspirant/deodorant compositions |
DE102010013274A1 (en) * | 2010-03-29 | 2011-11-17 | Beiersdorf Ag | Microbiologically stable, application-friendly preparations |
-
2019
- 2019-11-14 AU AU2019474692A patent/AU2019474692C1/en active Active
- 2019-11-14 MX MX2022005497A patent/MX2022005497A/en unknown
- 2019-11-14 CN CN201980102046.5A patent/CN114650805A/en active Pending
- 2019-11-14 WO PCT/US2019/061522 patent/WO2021096518A1/en unknown
- 2019-11-14 EP EP19817074.8A patent/EP4021387A1/en active Pending
- 2019-11-14 BR BR112022008793A patent/BR112022008793A2/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102004032734A1 (en) * | 2004-03-18 | 2005-10-06 | Henkel Kgaa | Prebiotic substances for deodorants |
EP2353579A1 (en) * | 2010-02-09 | 2011-08-10 | Unilever N.V. | Deodorant composition |
US20180177692A1 (en) * | 2016-12-27 | 2018-06-28 | Colgate-Palmolive Company | Antiperspirant / Deodorant Composition |
Also Published As
Publication number | Publication date |
---|---|
BR112022008793A2 (en) | 2022-10-04 |
CN114650805A (en) | 2022-06-21 |
MX2022005497A (en) | 2022-06-02 |
WO2021096518A1 (en) | 2021-05-20 |
AU2019474692C1 (en) | 2024-05-09 |
AU2019474692A1 (en) | 2022-05-26 |
EP4021387A1 (en) | 2022-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7976829B2 (en) | Antiperspirant/deodorant compositions | |
CN1299270A (en) | Antiperspirant compositions contg. 1,2-hexanediol | |
US6613312B2 (en) | Antiperspirant products made from wet-milled anhydrous antiperspirant salts | |
AU2019474692B2 (en) | Personal care compositions for treating odor causing bacteria and methods for the same | |
WO2018074439A1 (en) | Cosmetic | |
US11331253B2 (en) | Personal care compositions for treating odor causing bacteria and methods for the same | |
US10406085B2 (en) | Antiperspirant composition | |
US20170216156A1 (en) | Performance-enhanced antiperspirants | |
EP3493786B1 (en) | Active agent and method for reducing malodor | |
EP3171852B1 (en) | Antiperspirant compositions containing ethylenediamine disuccinate | |
JP2012219122A (en) | Novel silicone derivative | |
US20130230475A1 (en) | Antiperspirant emulsion products and processes for making the same | |
EP3027282A1 (en) | Antiperspirant/deodorant compositions | |
DE102015223837A1 (en) | Deodorants with metal particles and salts of carbon dioxide | |
US20230310289A1 (en) | Personal Care Compositions and Methods | |
JP2013213171A (en) | New silicone derivative | |
JP2013129721A (en) | Novel silicone derivative |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
DA2 | Applications for amendment section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 19 JAN 2024 |
|
DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 19 JAN 2024 |